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Abstract 
Xylella fastidiosa is a small, xylem-limited bacterium that causes a number of diseases in 
over 100 species of plants. Many of the species infected are economically important (such 
as coffee, grapevines, citrus, and almond) and billions of dollars worldwide are lost 
annually due to X. fastidiosa infection of crops. The bacterium colonises both plant and 
insect hosts, using the insect host to transfer it from plant to plant. Sequencing of the X. 
fastidiosa genome in 2000 discovered that while the genome is reduced, it contains a high 
number of putative bifunctional enzymes. One of these enzymes, aspartate 
kinase:diaminopimelate decarboxylase (AK:DapDc), occurs in only a handful of species 
and is predicted to catalyse the first and last steps of lysine biosynthesis. This study reports 
the first experimental characterisation of this enzyme. AK:DapDc was over-expressed in 
the pET30dSE plasmid in Escherichia coli BL21 DE3 cells. It was purified by Ni
2+
 His-
Trap chromatography followed by size exclusion chromatography. Homology models of 
AK:DapDc were created in SWISS-MODEL, which indicate homology with the aspartate 
kinase from Arabidopsis thaliana and the diaminopimelate decarboxylase from E. coli. 
Circular dichroism, and analytical ultracentrifugation were used to obtain information 
about the secondary and quaternary structure of AK:DapDc. This data, in combination with 
the homology models, suggests that AK:DapDc exists as a dimer or tetramer in solution. A 
coupled enzyme assay to assay for diaminopimelate decarboxylase activity has been set up, 
and preliminary crystal screens have been carried out. 
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1.   Introduction 
1.1   Xylella fastidiosa (subspecies fastidiosa) 
1.1.1   Introduction to the Xylella fastidiosa Bacterium 
Xylella fastidiosa is a small, rod-shaped, xylem-limited bacterium that causes a number of 
diseases in over 100 species of plants. These diseases include Pierce’s disease of 
grapevines (Vitis vinifera), phony peach disease in peach (Prunus persica), citrus 
variegated chlorosis in citrus (Citrus species), and several leaf scorch diseases in plants 
such as almond, coffee, plum, oleander and alfalfa
1
. Worldwide, billions of dollars are lost 
annually due to X. fastidiosa infection of economically important crops
2
. Symptoms of 
infection include leaf scorching (Figure 1.1A), smaller or dehydrated fruit (Figure 1.1B), 
leaf shedding, plant dieback, slowed growth and eventual death of the plant
1
. 
A. B. 
  
Figure 1.1 - Effects of Pierce's disease in grape, A. Leaf scorch caused by water stress, 
B. Dehydrated, shrivelled grapes on an affected grapevine. 
 
Pierce’s disease was first observed in the 1880’s3 and X. fastidiosa was first shown to be 
the causal agent in 1978
4
. The bacterium was described in 1987 and was named for its 
slow, fastidious growth habit
5
. Since then, many strains of X. fastidiosa have been 
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identified, partially sequenced, and classified into subspecies
6-10
. A comparative database 
established in 2012 provides information on all sequenced strains of X. fastidiosa 
(http://www.xylella.lncc.br)
11
. 
1.1.2   Plant Hosts of Xylella fastidiosa 
X. fastidiosa strains have a very broad host range and can infect over 100 species of plants. 
A full list of hosts can be found at http://www.cnr.berkeley.edu/xylella/control/hosts.htm
12
. 
Pierce’s disease-causing strains, such as X. fastidiosa subsp. fastidiosa, have a broad host 
range, but primarily cause disease in grapevines
13
. Some species of wild plants can act as 
reservoirs for the bacterium. These species are not affected by the bacterium, or are 
affected to a lesser extent, and the bacterium can remain dormant in these plants for a 
period of time
14
. Many reservoir species do not show symptoms of infection, but facilitate 
re-infection of nearby grapes
12
. Riparian grasses, sedges and trees growing next to 
vineyards have been identified as major reservoirs
14
. Several species of New Zealand 
native plants are predicted to be susceptible to infection by X. fastidiosa (e.g. pohutukawa -
Metrosideros excelsa), or have the potential to act as reservoirs
15
. Monterey pine (Pinus 
radiata), a major plantation species in New Zealand, is predicted to act as a reservoir
16
.  
1.1.3   Insect Hosts of Xylella fastidiosa 
While X. fastidiosa is largely thought of as a plant pathogen, both plant and insect hosts 
need to be colonized for X. fastidiosa to persist in an area
17
. Plants are infected by transfer 
of X. fastidiosa from an insect host to the plant. The bacterium dwells as a biofilm in the 
mouthparts and foregut of the insect vector until it feeds from a plant
18
. Feeding transfers 
X. fastidiosa to the plant where it migrates to the xylem and lodges, forming a biofilm. The 
most common vectors are the glassy winged sharpshooter and blue-green sharpshooter 
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(Figure 1.2), but other sharpshooter leafhoppers and spittlebugs are also vectors
19
. New 
Zealand leafhoppers and spittlebugs are predicted to be potential insect hosts for 
X. fastidiosa
12
.  
A. B. 
  
Figure 1.2 - The most common insect vectors for X. fastidiosa: A. The glassy-winged 
sharpshooter. B. The blue-green sharpshooter. 
1.1.4   Mechanism of Pathogenesis 
There is still debate over the mechanism of pathogenesis of X. fastidiosa
1
. Some symptoms 
such as wilting or leaf scorch suggest X. fastidiosa may be producing toxins. X. fastidiosa 
may also be causing a change in levels of plant-growth regulators
1
. Nitrogen metabolism is 
disturbed in diseased plants
20
. The mechanism with the most supporting evidence infers 
that X. fastidiosa causes blockage of the xylem, leading to water distress, leaf scorch, and 
eventual death of the plants
10
. 
1.1.5   Amino Acid Biosynthesis Genes in Reduced X. fastidiosa Genome  
In 2000, the complete genome of the 9a5c clone of X. fastidiosa was reported
6
. Since then, 
seven more X. fastidiosa strains have been fully sequenced
8, 11
 and ten strains have been 
partially sequenced (http://www.ncbi.nlm.nih.gov/genome/genomes/173). Simpson et al. 
(2000)
6
 were the first to publically report the full genome of a bacterial plant pathogen, and 
X. fastidiosa was found to have a reduced genome
6
. This occurs when a bacterium has a 
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significantly smaller genome compared to its ancestor. Bacteria with reduced genomes use 
their host organism’s processes to replace the lost functions21. This ‘streamlining’ of the 
bacterial genome may allow bacteria to replicate more often and use less energy, with the 
result being a more simple genome
22
. In contrast, bifunctional enzymes increase the 
complexity of genomes. Annotation of the 9a5c clone genome by Simpson et al. (2000) via 
BLAST and tRNAscan-SE
7
 noted that, in addition to having a reduced genome, X. 
fastidiosa has nine predicted bifunctional enzymes, a high number compared to other 
gammaproteobacteria (Table 1.1). Four of these proteins were predicted to be involved in 
amino acid biosynthesis: aspartate kinase:diaminopimelate decarboxylase (AK:DapDc), 
aspartate kinase:homoserine dehydrogenase I (AK:HSDH I), phosphoribosyl-ATP-
pyrophosphatase:phosphoribosyl-AMP-cyclohydrolase, and imidazole-glycerolphosphate 
dehydratase:histidinol-phosphate phosphatise. This is an interesting feature as many 
bacteria with reduced genomes have lost the genes necessary for biosynthesis of amino 
acids
21
. 
Table 1.1 - List of bifunctional enzymes predicted in X. fastidiosa's genome. 
Putative bifunctional enzyme Pathway 
aspartate kinase: diaminopimelate decarboxylase (AK:DapDc) 
lysine biosynthesis 
aspartate kinase: homoserine dehydrogenase I (AK:HSDH I) 
threonine biosynthesis 
phosphoribosyl-ATP-pyrophosphatase: phosphoribosyl-AMP-
cyclohydrolase (PRA-PH-PRA-CH) 
histidine biosynthesis 
imidazole-glycerolphosphate dehydratase: histidinol-
phosphate phosphatise (IGPD:HPP) 
histidine biosynthesis 
bifunctional purine biosynthesis protein (purH) 
inosine 5-phosphate 
biosynthesis 
bifunctional methylenetetrahydrofolate dehydrogenase/ 
methenyltetrahydrofolate cyclohydrolase (fold) 
formyl THF biosynthesis 
bifunctional penicillin-binding protein 1C precursor (pbpC) 
peptidoglycan biosynthesis 
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Putative bifunctional enzyme Pathway 
dGTP-pyrophosphohydrolase/ thiamine phosphate synthase 
(mutt/thiE1) 
DNA replication and repair/ 
thiamine (cofactor) synthesis 
transcriptional repressor of the biotin operon/ biotin acetyl-
CoA-carboxylase synthetase (birA/bioR/dhbB) 
biotin metabolism 
 
1.2   Bifunctional Enzymes 
Bifunctional enzymes are one type of multifunctional enzyme. Enzymes can be 
multifunctional because they have promiscuous activity and recognise several substrates, 
for example cytochrome P450 mono-oxygenases which act on a wide range of toxic 
substrates
23
. Some multifunctional enzymes can produce multiple products from the same 
substrate, for example toluene 4-monooxygenase, which produces four different 
hydroxylation products from toluene
23
. Moonlighting enzymes are multifunctional because 
they catalyse a specialised reaction, but also have another role in the cell which is 
structural or regulatory, for example hexokinase from Arabidopsis species converts glucose 
to glucose-6-phosphate and also regulates a number of genes in response to intracellular 
glucose levels
24, 25
.  
Bifunctional enzymes are multifunctional because they have two distinct active sites on a 
single protein that catalyse different specialised reactions
26
, which are often part of the 
same metabolic pathway. The two domains are encoded by one gene and are translated as 
one polypeptide. Bifunctional enzymes are found primarily in gammaproteobacteria and 
arise from the fusion of two genes encoding the two functions and the loss of any upstream 
promoter regions for one of those genes
27
. In theory, the presence of bifunctional enzymes 
can “allow increased coordination of gene expression”, but bifunctional enzymes are 
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actually quite rare despite this apparent advantage
24
. This is likely due to the fact that they 
arise as a result of random mutations which fuse two genes together. 
Bifunctional enzymes can catalyse either two consecutive reactions, two non-consecutive 
reactions or two opposing reactions
26
. Catalysing two consecutive reactions can allow for 
substrate channelling from one active site to the other, reducing the loss of substrates to 
unwanted side reactions and diffusion. Many bifunctional enzymes that catalyse 
consecutive reactions do not exhibit channelling, suggesting this property is not as 
common as once believed
26
. Catalysing two non-consecutive reactions from the same 
pathway co-localizes the functions without having to form multi-protein complexes and 
can also be useful for regulation of the pathway
24
. The product of one reaction may bind 
allosterically to the enzyme and inhibit the other reaction quickly. 
Another theory on the regulation and inhibition of bifunctional enzymes has recently been 
put forward. It is now being suggested that bifunctionality allows one domain/function to 
interact with the other function to cause a conformational change affecting activity and/or 
affinity, as opposed to the product of one domain’s reaction allosterically inhibiting the 
other function
26
. Conformational changes that activate or deactivate domains may be 
transmitted from one domain to the other through an unstructured linker region which is in 
a particular conformational state. Interaction of one domain with the other, communicated 
via the linker, could be repressing the activity of the other site. Thus a linker between 
domains, and its conformational state, could be crucial for stabilizing domain(s). Some 
enzymes that have linkers, such as lysine-ketoglutarate reductase: saccharopine 
dehydrogenase of Arabidopsis thaliana, are sensitive to sodium chloride concentration
26
. 
The effect of sodium chloride on enzyme activity might be mediated by salt-induced 
changes in the linker. In this case, the linker may determine the nature of enzyme 
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conformational changes. One of the predicted bifunctional enzymes in X. fastidiosa, 
aspartate kinase:diaminopimelate decarboxylase, is predicted by the conserved domains 
database (CDD)
28
 to have two separate conserved domains connected by a linker of 
approximately 30 amino acids. The state of the linker may affect the stability of one or 
both domains, making expression and purification more difficult, according to the above 
theory.  
1.3   Lysine Biosynthesis 
There are four known pathways that synthesise lysine from aspartate: the succinylase 
pathway, the acetylase pathway, the aminotransferase pathway, and the dehydrogenase 
pathway (Figure 1.3)
29
. The four pathways diverge after step four of the overall pathway. 
After the second reaction of lysine biosynthesis there is a branch point where the 
metabolite can be committed to lysine biosynthesis or funnelled into threonine, methionine 
or isoleucine biosynthesis. Meso-diaminopimelate can either be converted to lysine or used 
as a component of the bacterial cell wall. After the reaction carried out by 
dihydrodipicolinate synthase, the metabolite (S)-tetrahydrodipicolinate can be used by 
enzymes from any of the four pathways to synthesise lysine. These pathways also branch 
off into threonine, methionine, and isoleucine biosynthesis after the second step of the 
pathway, and to peptidoglycan biosynthesis before the last step. Plants utilise the 
succinylase or dehydrogenase pathways, whereas bacteria can use any of the four 
pathways
29
. Lysine biosynthesis genes (DapA-DapF) show a high level of co-expression, 
although they do not exist in an operon
27
. X. fastidiosa is predicted to synthesise lysine via 
the succinylase pathway
6
. 
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Figure 1.3 - Lysine biosynthesis pathways. Diagram drawn in Chemdraw. 
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Lysine biosynthesis is an essential pathway in X. fastidiosa subsp. fastidiosa and other 
xylem-dwelling bacteria. The xylem sap contains “a diversity of amino acids, organic 
acids, and inorganic ions”30, but xylem-dwelling bacteria still need to synthesise a number 
of amino acids themselves. Xylem sap does not contain lysine, and X. fastidiosa’s insect 
hosts do not synthesise lysine either. 
Essential lysine biosynthesis enzymes have the potential to be used as antibiotic targets, as 
they are not present in animals and thus have high specificity for bacteria and low toxicity 
in humans, animals, and plants
31, 32
. Due to the branched nature of lysine biosynthesis, 
inhibition of this pathway could affect all of these branches and prevent cell wall cross-
linking. Meso-diaminopimelate is one of the D- amino acids that forms a short chain of 
amino acids to crosslink the rows of sugars (N-acetylglucosamine and N-acetylmuramic 
acid) in the cell wall. The reactions in lysine biosynthesis are not strictly essential to 
bacteria
32
, but for the slow growing X. fastidiosa that may have evolved more specialized 
regulatory mechanisms, it could be essential and be a feasible antibacterial target.  
Two of the predicted bifunctional enzymes in X. fastidiosa, AK:DapDc and AK:HSDH I, 
have roles in lysine biosynthesis. Both of these enzymes catalyse non-consecutive 
reactions (Figure 1.3), and occur at branch points in lysine biosynthesis, so their regulatory 
properties are of particular interest. 
AK:HSDH I catalyses the first and third steps of lysine biosynthesis. The first step 
converts aspartate and adenosine triphosphate (ATP) to aspartyl 4-phosphate and adenosine 
diphosphate (ADP), committing aspartate to the aspartate-derived amino acid biosynthesis 
pathway. The third step of lysine biosynthesis is a branch point where the substrate can be 
directed into threonine synthesis or lysine synthesis. The HSDH I function commits the 
metabolite to threonine synthesis and is regulated by threonine. The AK:HSDH I gene is 
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more widespread/prevalent than AK:DapDc and occurs in many gammaproteobacteria
33, 34
. 
It is suggested that duplication of the AK gene (ask) was rapidly followed by fusion to the 
HSDH I gene (hom) as only Vibrio species of bacteria have two monofunctional ask genes 
(Figure 1.6)
27
. 
AK:DapDc is predicted to catalyse the first and last (ninth) steps of lysine biosynthesis. 
The AK domain catalyses the phosphorylation of aspartate to give aspartyl 4-phosphate. 
The last reaction converts meso-diaminopimelate to lysine and carbon dioxide, and occurs 
at a branch point between lysine biosynthesis and peptidoglycan synthesis. AK:DapDc 
could regulate the lysine synthesis pathway by feedback inhibition of the first step by the 
product of the last step. Its function is still putative and is only predicted to occur in a 
handful of species in the family Xanthomonadaceae. This study investigates the 
bifunctional AK:DapDc enzyme, as it is very rare and its function is still putative. 
1.4   Aspartate kinase:diaminopimelate decarboxylase 
The AK:DapDc gene from X. fastidiosa encodes the conserved domains for both functions, 
which are connected by a linker of approximately 30 amino acids
6
. The functions of this 
enzyme are still putative, that is, the functions are computationally predicted
35
, but have 
not yet been experimentally confirmed. This gene is not found in an operon, unlike the 
other predicted bifunctional enzymes in X. fastidiosa
6, 27
.  
AK is an enzyme encoded by the ask or LysC gene. There are three types of aspartate 
kinases (I, II and III), with AK type III being the ancestral type
27
. Types I and II are 
bifunctional with HSDH I and II, respectively, in all gammaproteobacteria
27
. Each of these 
types is regulated by different end-product(s): type I is inhibited by threonine and 
isoleucine
36
, type II is inhibited by methionine
33
 and type III is inhibited by lysine
37
. The 
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aspartate kinase in AK:DapDc is a type III aspartate kinase
27
 and is predicted to be 
allosterically inhibited by lysine. 
AK catalyses the conversion of aspartate to L-4-aspartylphosphate (Figure 1.4). This 
reaction commits aspartate to aspartate-derived amino acid synthesis. The reaction is 
driven by the hydrolysis of ATP to ADP and requires a magnesium ion bound in the active 
site. The structures of 20 bacterial AKs have been fully or partially solved (PDB). Some 
research has focussed on just the regulatory domain of AK
38-40
. AK has an N-terminal 
catalytic domain and a C-terminal regulatory domain. The regulatory domain consists of 
multiple repeats of an aspartate kinase: chorismate mutase: TyrA (ACT) domain
41
. Each 
ACT domain has a binding site for an inhibitor and evolves independently of neighbouring 
ACT domains
42
. The catalytic domain has two lobes (N- and C-terminal lobes) and the 
active site of the enzyme lies between them
43
. 
 
 
Figure 1.4 - Aspartokinase reaction: aspartate is phosphorylated by aspartate kinase, 
to produce L-4-aspartylphosphate.  
 
Diaminopimelate decarboxylase (DapDc) is an enzyme encoded by the lysA gene. It takes 
meso-2,6-diaminopimelate and stereospecifically removes a carboxyl group to give L-
lysine (Figure 1.5)
44
. DapDc requires pyridoxal 5-phosphate (PLP) as a cofactor. This is an 
unusual reaction for a PLP-dependent decarboxylase, as it stereospecifically converts a 
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D,L-enantiomer into an L-product, thus removing the D-stereocenter and resulting in 
inversion of configuration
45, 46
. DapDc is also allosterically inhibited by lysine. 
 
Figure 1.5 - Diaminopimelate decarboxylase reaction: the stereospecific 
decarboxylation of meso-2,6-diaminopimelate decarboxylase to produce L-lysine and 
carbon dioxide. 
 
DapDc is a TIM-barrel enzyme with an additional β-sandwich domain. This makes it a fold 
type IV of PLP-dependent enzymes, which are homologs of alanine racemase, and are 
structurally similar to ornithine and arginine decarboxylases
47, 48
. DapDc is an obligate 
dimer, and dimerises in a “head-to-tail” fashion49.The active site is located at the dimer 
interface and both subunits contribute residues to the active sites. Eleven bacterial and two 
archaeal DapDc enzyme structures have been crystallographically solved (PDB). 
1.4.1.1   Proposed Mechanism of AK:DapDc Evolution 
AK:DapDc is presumed to have evolved through random gene duplication of ask due to 
genetic drift (Figure 1.6)
27
. Only gammaproteobacteria contain multiple copies of the ask 
gene
27
. The ask gene duplicated in the gammaproteobacterial ancestor and one copy 
rapidly fused to the hom gene encoding HSDH to produce ask-hom. Species of gamma-
proteobacteria group into two clusters: species in cluster one have only one ask-hom gene, 
while those in cluster two have two ask-hom genes due to a subsequent gene duplication
27
. 
The duplicate ask-hom gene was under less/no selection pressure compared to the original 
gene and this allowed for divergence of the two genes and specialisation
50
. In the 
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Xanthomonadaceae family, the monofunctional ask gene fused to LysA. ask-LysA contains 
the conserved domains encoding a type III AK. X. fastidiosa’s other AK is a type I AK 
(fused to HSDH I). 
 
Figure 1.6 - Diagram of AK:DapDc (ask-LysA) evolution adapted from Fondi et al. 
(2007)
27
. The ask gene duplicated in the ancestral bacteria due to random mutation. 
One of the ask genes became fused to the hom gene encoding HSDH. In 
gammaproteobacteria (cluster 1) the fused ask-hom did not duplicate, but in the 
Xanthomonadaceae family the monofunctional ask gene fused to the LysA gene 
encoding DapDc. 
 
These gene duplication and gene fusion events allow for rapid diversification and 
exploration of sequence space
50, 51
. The ancestral, monofunctional AK may have been 
regulated to some degree by lysine, methionine, threonine, and isoleucine, but the 
regulation mechanism was unspecific
52
. Duplication, diversification and gene fusion has 
allowed the AKs to become sensitive to different signals, i.e. each is now regulated by a 
different end product, giving each an individual cellular role and fine-tuning the flux of 
aspartate-derived amino acid biosynthesis. 
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1.5   Scope of this Thesis 
The overall aim of this thesis was to characterise the AK:DapDc enzyme from X. fastidiosa 
subsp. fastidiosa.  This enzyme is of interest because it is one of many bifunctional 
enzymes encoded in the X. fastidiosa genome – an interesting feature in a reduced bacterial 
genome. Characterising this protein will add to the current knowledge base on enzyme 
bifunctionality and why this trait has evolved. 
The first aim of this study was to over-express AK:DapDc and to purify the protein. The 
second aim was to biophysically characterise the protein using a range of methods that 
would investigate the secondary and quaternary structure of AK:DapDc, supported by 
computational data such as homology models. The third aim was to set up an activity assay 
in order to confirm the predicted functions of the enzyme.  
I hypothesise that this enzyme may occur in solution as a dimer or tetramer, as both 
monofunctional forms of AK and DapDc are reported to occur as dimer and tetramer. I also 
hypothesise that AK:DapDc catalyses both predicted reactions, and is inhibited by lysine. 
If true, this would suggest that AK:DapDc regulates metabolite entry into lysine 
biosynthesis by inhibiting the first step in the pathway. 
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2.   Methods and Materials 
2.1   Experimental Reagents 
2.1.1   Chemical Reagents 
All buffers, reactions, and solutions requiring water utilised pyrogen-free, DNase-free, 
ultrapure type 1 Milli-Q water dispensed from a Milli-Q Reference fitted with a BioPak 
Polisher (Merck Millipore, Billerica, Massachusetts, USA). Unless specifically stated 
otherwise, general chemicals used to make buffers and solutions were purchased from a 
number of suppliers including Amersham Biosciences, Bioline, Life Technologies, Merck, 
Sigma-Aldrich, and Thermo Fisher Scientific. 
2.1.2   Biological Materials 
Xylella fastidiosa subsp. fastidiosa (ICMP 15197) genomic DNA (25 ng/μL) was sourced 
from Landcare Research. Primers were supplied by Integrated DNA Technologies (IDT, 
Singapore). The His-tagged Saccharomyces cerevisiae saccharopine dehydrogenase (SDH) 
gene in the pET16b vector was supplied by Matthew Perugini’s lab group at LaTrobe 
University (Melbourne, Australia). Restriction enzymes and their associated buffers were 
supplied by New England BioLabs Inc. (NEB, Ipswich, Massachusetts, USA). The vector 
pCR™2.1-TOPO®, part of the pCR2.1TOPO® TA Cloning® Kit used for cloning, was 
supplied by Invitrogen (Invitrogen™ by Life Technologies™, Carlsbad, California, USA). 
Lysozyme from chicken egg white was obtained from Sigma-Aldrich (St. Louis, Missouri, 
USA). 
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2.1.3   General Equipment 
All eppendorf tubes and pipette tips used throughout all experiments were sterilised by 
autoclaving at 121°C for 20 minutes and were allowed to cool prior to use. Large cultures 
were centrifuged in the SorvallTM RC 6 Plus Centrifuge (Thermo Scientific, Waltham, 
Massachusetts, USA) using the fixed angle F10S-6x500y rotor, while samples of 50 mL or 
less were centrifuged using the Eppendorf Centrifuge 5810R (Eppendorf, Hamburg, 
Germany) with the fixed angle rotors F34-6-38 and F45-30-11. 
A Minitron incubator shaker (Infors HT, Bottmingen, Switzerland) was used for the 
incubation of all bacterial cell cultures. DNA concentrations were measured using a 
Nanodrop Spectrophotometer ND-1000 (Thermo Scientific, Wilmington, Delaware, USA). 
Buffers were filtered either through a Whatman™ Klari-Flex™ 250 mL 0.22 μm PES Filter 
Funnel (Fisher Scientific, Loughborough, UK) or through a 33 mm Millex-GV 0.22 μm 
PVDF syringe filter (Merck Millipore, Billerica, Massachusetts, USA). Finally, all pH 
measurements were performed using the UltraBasic pH/mV meter (Denver Instrument, 
Bohemia, New York, USA). 
2.1.4   Standard Solutions 
Antibiotics were made up as concentrated stock solutions. Kanamycin (kan) (kanamycin 
sulphate, Roche, Indianapolis, Indiana, USA) stock solutions were made up in water at 
100 mg/mL, filter sterilised with a 0.22 μm filter and used in media at a final concentration 
of 100 μg/mL. Ampicillin (amp) (ampicillin sodium salt; Applichem, Darmstadt, Germany) 
was prepared in water at 100 mg/mL, filter sterilised with a 0.22 μm filter and used in 
media at a final concentration of 100 μg/mL. Chloramphenicol (cam) (Roche, Indianapolis, 
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Indiana, USA) was prepared in 100% ethanol at 30 mg/mL, filter sterilised with a 0.22 μm 
filter and used in media at a final concentration of 30 μg/mL. 
Diaminopimelate (Sigma-aldrich, D1377- a mixture of LL-, DD-, meso-) was made as a 
concentrated stock solution of 20 mM in water. L-lysine was made as a stock of 40 mM in 
water. Pyridoxal phosphate stocks were made up in water to a concentration of 20 mM. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was made up in water as a stock of 1 M. 
All stock solutions were stored at -20°C, unless otherwise specified. 
2.2   Molecular Biology 
2.2.1   Bacterial Strains, Plasmids, Genes, and Primers 
2.2.1.1   Bacterial Strains 
Escherichia coli XL-1 Blue (standard laboratory strain) cells were used for cloning. E. coli 
BL21 (DE3) cells were used throughout this study for protein expression. E. coli BL21 
(DE3) Rosetta cells were used in expression trials. The Rosetta cells contained the pRARE 
plasmid, which confers chloramphenicol resistance and contains rare tRNA genes. 
2.2.1.2   Plasmids 
Cells were transformed with vectors listed in Table 2.1, containing either the gene for 
AK:DapDc (Table 2.3) or SDH. Plasmids pCR2.1-TOPO-XF, pBluescript-XF, pET30ΔSE-
HisXF, and pET30ΔSE-XF were constructed using the protocols described in sections 
2.2.4-2.3.1 below. Maps for these plasmids are found in Appendix II. 
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Table 2.1 - List of plasmids used in this study. 
Plasmid Name 
(Parent plasmid) Purpose 
Antibiotic 
Resistance Insert 
pCR2.1-TOPO-XF 
(pCR2.1-TOPO) 
Cloning vector kanR, ampR 
XFLM_07435 - 
X. fastidiosa AK:DapDc gene 
pBluescript-XF 
(pBluescript SK+) 
Cloning vector ampR 
XFLM_07435 - X. fastidiosa 
AK:DapDc gene 
pET30ΔSE-XF 
(pET30ΔSE) 
Expression vector kanR 
XFLM_07435 - X. fastidiosa 
AK:DapDc gene 
pET30ΔSE-HisXF 
(pET30ΔSE) 
Expression vector kanR 
XFLM_07435 – His-tagged X. 
fastidiosa AK:DapDc gene 
pET16b-SDH 
(pET16b) 
Expression vector ampR, camR 
Saccharomyces cerevisiae 
Saccharopine Dehydrogenase 
(SDH) gene 
 
2.2.1.3   XFLM_07435 
The AK:DapDc gene (XFLM_07435) sequence was determined by sequencing (Table 2.3) 
and is identical to other AK:DapDc genes from X. fastidiosa subsp. fastidiosa strains 
already sequenced (e.g. X. f. fastidiosa GB514). 
2.2.1.4   Primers 
The primers used in this study (Table 2.2) were obtained from Integrated DNA 
Technologies (IDT, Singapore). All primers were resuspended in MilliQ water to a final 
concentration of 100 μM. Primer pair oRD53(F) and oRD54(R) were used to clone a 
pET30ΔSE-HisXF construct with an N-terminal His-tag. The primer pair oRD55(F) and 
oRD54(R) were used to engineer NdeI and HindIII restriction sites to create a pETΔSE-XF 
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construct with no tags. The forward primer oRD56(F) anneals approximately one third of 
the way along the XFLM_07435 and was used in conjunction with the T7 vector primers 
to sequence the XFLM_07435 gene. Two primers are not sufficient to sequence the entire 
gene accurately. 
Table 2.2 - Primers used in this study. 
Primer Name and Sequence 
Restriction 
Site 
Melting 
Temperature 
oRD53(F): 5’ GAG CTC ATG TCC GCT TCC CCT ACA GC 
3’ 
SacI Tm= 64.6°C 
oRD54(R): 5’ AAG CTT TCA AGC ATC AAG CAC GAC 
CTC G 3’ 
HindIII Tm= 62.9°C 
oRD55(R): 5’ CAT ATG TCC GCT TCC CCT ACA GCC 3’ NdeI Tm= 61.3°C 
oRD56(F): 5’ GGA CAC GTC AGC AGC ATA TTT TGG TGC 
G 3’ 
 Tm= 63.5°C 
 
Table 2.3 - Gene sequence of XFLM_07435 from X. fastidiosa subsp. fastidiosa (ICMP 
15197) as determined by sequencing, and translated amino acid sequence. 
   1 ATGTCCGCTTCCCCTACAGCCGAGCGCTGGATCGTTCTAAAATTTGGTGGTACTTCCGTA 
  +1 M  S  A  S  P  T  A  E  R  W  I  V  L  K  F  G  G  T  S  V   
                                                                  
  61 TCGCGTCGTCATCGCTGGGACACCATTGCGATGGTGGTGAGGAAGCGCCTTGAAGAGCAT 
  +1 S  R  R  H  R  W  D  T  I  A  M  V  V  R  K  R  L  E  E  H   
                                                                  
 121 GGAACACGTGTACTGATCGTGGTTTCGGCGCTGTCTGGCGTGACCAATGAACTGACGGCG 
  +1 G  T  R  V  L  I  V  V  S  A  L  S  G  V  T  N  E  L  T  A   
                                                                  
 181 ATTGCTCAAGGTGTTGTGGACAGTGCCAAGCGCGTCACTGCATTGGAGCAGCGTCATCGC 
  +1 I  A  Q  G  V  V  D  S  A  K  R  V  T  A  L  E  Q  R  H  R   
                                                                  
 241 GATTTTTTGGTTGAGCTTGGGTTAGATGCGCAAGCTGTGCTCGGCACGCGTTTCGCCATG 
  +1 D  F  L  V  E  L  G  L  D  A  Q  A  V  L  G  T  R  F  A  M   
                                                                  
 301 TTGTCGGATCTTCTGCAAGATGCGCGTGCGGTGACGCGGTCACTGGACTGGCAGGCTGAG 
  +1 L  S  D  L  L  Q  D  A  R  A  V  T  R  S  L  D  W  Q  A  E   
                                                                  
 361 TTGTTAGGGCAAGGTGAACTGTTGTCTTCCACACTCGGTGCGGCCTACCTGGGTGCTTCG 
  +1 L  L  G  Q  G  E  L  L  S  S  T  L  G  A  A  Y  L  G  A  S   
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 421 GGTATTGATATCGGTTGGATGGATGCACGTGACTGGCTGACCGCTTTACCACCACAGCCC 
  +1 G  I  D  I  G  W  M  D  A  R  D  W  L  T  A  L  P  P  Q  P   
                                                                  
 481 AACCAGAGTGAATGGTCGCAACGTCTTTCTGTCTCCTGTCAATGGAAGTCTGATGTGGAG 
  +1 N  Q  S  E  W  S  Q  R  L  S  V  S  C  Q  W  K  S  D  V  E   
                                                                  
 541 TGGCGTACACGTTTCGATGCCCAACGTGCTCAGGTATTGATCACTCAAGGGTTTATCTCA 
  +1 W  R  T  R  F  D  A  Q  R  A  Q  V  L  I  T  Q  G  F  I  S   
                                                                  
 601 CGTCATCAAGATGGTGGTACCGCCATCCTGGGACGTGGTGGTTCGGACACGTCAGCAGCA 
  +1 R  H  Q  D  G  G  T  A  I  L  G  R  G  G  S  D  T  S  A  A   
                                                                  
 661 TATTTTGGTGCGCTACTTGGTGCGGCGTGTGTTGAGATCTGGACTGATGTACCAGGGATG 
  +1 Y  F  G  A  L  L  G  A  A  C  V  E  I  W  T  D  V  P  G  M   
                                                                  
 721 TTCAGTGCGAACCCGAAGGAGGTCCCTGATGCGCGTTTGCTGACGCGCCTGGATTACTAC 
  +1 F  S  A  N  P  K  E  V  P  D  A  R  L  L  T  R  L  D  Y  Y   
                                                                  
 781 GAGGCACAGGAGATCGCCACAACTGGCGCGAAGGTGTTGCATCCGCGTTCGATCAAACCA 
  +1 E  A  Q  E  I  A  T  T  G  A  K  V  L  H  P  R  S  I  K  P   
                                                                  
 841 TGCCGTGATACTGGCGTGCCGATGCTGATTCTAGATACTGAGCGGCCCGATGTGTTGGGG 
  +1 C  R  D  T  G  V  P  M  L  I  L  D  T  E  R  P  D  V  L  G   
                                                                  
 901 ACCCGTATTGATGCTGAAGTTGAGCCGGTGCTTGGAGTCAAGGCGATTAGCCGTCGTGAT 
  +1 T  R  I  D  A  E  V  E  P  V  L  G  V  K  A  I  S  R  R  D   
                                                                  
 961 GGCATTGTATTAGTGTCGATGGAAGGGATCGGCATGTGGCAGCAGGTGGGTTTTCTTGCT 
  +1 G  I  V  L  V  S  M  E  G  I  G  M  W  Q  Q  V  G  F  L  A   
                                                                  
1021 GACGTATTTACATTGTTCAAGAAACACGGATTGTCGGTGGACCTCATCGGATCGGCAGAA 
  +1 D  V  F  T  L  F  K  K  H  G  L  S  V  D  L  I  G  S  A  E   
                                                                  
1081 ACCAATGTTACTGTGTCCTTGGACCCCTCCGAGAACCTGGTTAACACCGACGTACTGACT 
  +1 T  N  V  T  V  S  L  D  P  S  E  N  L  V  N  T  D  V  L  T   
                                                                  
1141 GCATTGTCAACCGATTTATCACAGATCTGCAAAGTCAAAATTATTGTGCCTTGCGCTGCG 
  +1 A  L  S  T  D  L  S  Q  I  C  K  V  K  I  I  V  P  C  A  A   
                                                                  
1201 ATCACTTTGGTCGGGCGTGGTATGCGTTCCCTGCTGCATAAACTCTCTGAGGTATGGGCT 
  +1 I  T  L  V  G  R  G  M  R  S  L  L  H  K  L  S  E  V  W  A   
                                                                  
1261 ACGTTCGGTAAAGAACGTGTCCACATGATCTCGCAGTCTTCCAATGATCTTAATCTCACC 
  +1 T  F  G  K  E  R  V  H  M  I  S  Q  S  S  N  D  L  N  L  T   
                                                                  
1321 TTTGTGATTGATGAGACTGATGCGGACGGATTATTGGCGGTGCTGCATTTCAAATTGATC 
  +1 F  V  I  D  E  T  D  A  D  G  L  L  A  V  L  H  F  K  L  I   
1381 GAAAGTGGTGCAATGCCTGTCCAAGATCGTGCCGTGTTTGGTTCGCCTTGGCGCGAGATC 
  +1 E  S  G  A  M  P  V  Q  D  R  A  V  F  G  S  P  W  R  E  I   
                                                                  
1441 ATCGGGCACGTACGTACGCGGGTCATGCCTTGGTGGCACAGTGCCCGCATGCGTTTACTG 
  +1 I  G  H  V  R  T  R  V  M  P  W  W  H  S  A  R  M  R  L  L   
                                                                  
1501 GCCATGAGAGATGAAGAGGGCATTGGTCCTTGCTACGTCTACCATTTGCCGACAGTGCGC 
  +1 A  M  R  D  E  E  G  I  G  P  C  Y  V  Y  H  L  P  T  V  R   
                                                                  
1561 GAACGTGCGCGGCAATTGAATGCAGTAGCTGCCGTGGATCAGTGCTACTACGCCATCAAG 
  +1 E  R  A  R  Q  L  N  A  V  A  A  V  D  Q  C  Y  Y  A  I  K   
                                                                  
1621 GCCAACCCGCATCCGGCCATTCTCCGTACCCTGATTGAAGAAGGCTTTGGACTAGAGTGC 
  +1 A  N  P  H  P  A  I  L  R  T  L  I  E  E  G  F  G  L  E  C   
                                                                  
1681 GTGTCATTGGGTGAATTGCGTCACGTGTTTGAAGTGGTGCCACACTTGGTTCCGTCGCGT 
  +1 V  S  L  G  E  L  R  H  V  F  E  V  V  P  H  L  V  P  S  R   
                                                                  
1741 GTGTTATTCACTCCAAGTTTCGCCTCACGTGTGGAGTACGAGCAGGCATTCTTACTAGGT 
  +1 V  L  F  T  P  S  F  A  S  R  V  E  Y  E  Q  A  F  L  L  G   
                                                                  
Methods and Materials 25 
 
 
1801 GTCAATGTGACCTTGGACAATGTCGAGGCCTTGCGCTTATGGCCGGAGGTATTCCGTGAA 
  +1 V  N  V  T  L  D  N  V  E  A  L  R  L  W  P  E  V  F  R  E   
                                                                  
1861 CGGACGTTATGGTTACGTATCGATTTGGGTTACGGCGATGGACATCACGAGAAGGTCACC 
  +1 R  T  L  W  L  R  I  D  L  G  Y  G  D  G  H  H  E  K  V  T   
                                                                  
1921 ACCGGTGGTAAGACATCTAAATTTGGCCTTTCGGTCACGCGGATTGATGAATTTATCGAT 
  +1 T  G  G  K  T  S  K  F  G  L  S  V  T  R  I  D  E  F  I  D   
                                                                  
1981 GTTGCCAAGACACTGAACATAACCGTGACCGGCCTGCATGCCCATCTTGGCAGTGGCGTG 
  +1 V  A  K  T  L  N  I  T  V  T  G  L  H  A  H  L  G  S  G  V   
                                                                  
2041 GAGAGCGGCAACCATTGGTCTCGCATGTACGATGAGTTGGCTGGTTTTGCCTCCCGCATC 
  +1 E  S  G  N  H  W  S  R  M  Y  D  E  L  A  G  F  A  S  R  I   
                                                                  
2101 GGGAGTGTGTCTACCCTGGATATCGGCGGCGGCTTACCGATCCCGTACCGGCCTGATGAT 
  +1 G  S  V  S  T  L  D  I  G  G  G  L  P  I  P  Y  R  P  D  D   
                                                                  
2161 GAACCATTTGACGTGGGGGCGTGGGGAGCAAGTTTGGCTGAAGTCAAAGCCTTGCATCCC 
  +1 E  P  F  D  V  G  A  W  G  A  S  L  A  E  V  K  A  L  H  P   
                                                                  
2221 AAATTTCAATTGGTGATTGAGCCGGGCCGCTTCCTTGTAGCCGAAGCGGGCGTGCTCTTG 
  +1 K  F  Q  L  V  I  E  P  G  R  F  L  V  A  E  A  G  V  L  L   
                                                                  
2281 ACCAGGGTCACCCAAGTGATTGAAAAAGATGACATCCTTCGGGTTGGCCTGGAGGCTGGC 
  +1 T  R  V  T  Q  V  I  E  K  D  D  I  L  R  V  G  L  E  A  G   
                                                                  
2341 ATGCATACCCTGATTCGTCCGGCCCTTTACGATGCCTGGCACGGCGTGGAGAACCTCACC 
  +1 M  H  T  L  I  R  P  A  L  Y  D  A  W  H  G  V  E  N  L  T   
                                                                  
2401 CGCTTGGATGAGACACCCCATGTACTGTGCGATGTCGTGGGTCCTATTTGCGAGTCATCC 
  +1 R  L  D  E  T  P  H  V  L  C  D  V  V  G  P  I  C  E  S  S   
                                                                  
2461 GACGTGTTTGGCCGTCGCCGTCACCTTCCAGCCGCCACCGCCTCCGGTGATTTAATGTTG 
  +1 D  V  F  G  R  R  R  H  L  P  A  A  T  A  S  G  D  L  M  L   
                                                                  
2521 ATTGCAGATGCTGGCGCCTATGGTTTCTCGATGGCCAGCACTTACAATCTGCGCGGCCTG 
  +1 I  A  D  A  G  A  Y  G  F  S  M  A  S  T  Y  N  L  R  G  L   
                                                                  
2581 CCGGCCGAGGTCGTGCTTGATGCCTGA 
  +1 P  A  E  V  V  L  D  A  *   
 
2.2.2   Agar Plates 
Luria-Bertani (LB) broth base (Invitrogen™, by Life Technologies™, Carlsbad, California, 
USA) (20 g/L) was added to agar (15 g/L) and mixed thoroughly. The LB-agar mix was 
autoclaved and left to cool to approximately 50°C before adding the relevant antibiotic. 
Autoclaved LB-agar was stored at room temperature and melted in a microwave when 
needed. Molten LB-agar was poured into sterile petri dishes in a laminar flow hood. 
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2.2.3   Competent Cells 
Competent E. coli cells stored at -80°C were; taken out of the freezer and a loop of cells 
was streaked out in a quadrant pattern on an LB agar plate containing no antibiotics. This 
plate was incubated at 37°C overnight. Single colonies were added to 3 mL pre-cultures 
(LB with no antibiotics) and placed on a shaker in a 37°C room overnight. A fraction of the 
pre-cultures (500 μL) was added to 25 mL of LB. These larger cultures were incubated at 
37°C. When the O.D.600 reached 0.6–0.8, the cultures were put on ice. Then they were 
centrifuged at 3,000 rpm for five minutes at 4°C. The media was discarded and the cells 
were resuspended in 30 mL of ice cold calcium chloride (132 mM). The cells were 
incubated on ice for 30 minutes, then centrifuged at 3,000 rpm for five minutes at 4°C and 
the supernatant removed. The cells were resuspended in 2 mL of calcium chloride and 
1 mL of 50% glycerol. Aliquots of 100 μL were pipetted into eppendorfs and flash frozen 
in liquid nitrogen. The cells were stored at -80°C. To test that the cells contained no 
contaminating plasmids, newly made competent cells were plated on LB agar containing 
ampicillin, kanamycin or no antibiotics. Cells that grew on the plates containing antibiotics 
were rejected as being contaminated. If the competent cells grew only on the plate without 
antibiotics they were considered satisfactory. 
2.2.4   Polymerase chain reaction 
Amplification of the AK:DapDc gene (XFLM_07435, Table 2.3) was carried out using 
Platinum® Taq DNA Polymerase High Fidelity (Invitrogen™ by Life Technologies™, 
Carlsbad, California, USA). The 10x High Fidelity PCR Buffer, 50 mM magnesium 
sulphate, and 50 mM dNTP mix was supplied with the Platinum® Taq DNA Polymerase. 
PCR reactions were run on a Multigene™ PCR Thermal Cycler (LabNet International Inc., 
Edison, New Jersey, USA).  
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For the initial amplification of the XFLM_07435 gene, 10 μL of 25 ng/μL genomic DNA 
was used. For most PCR reactions, 100 ng of DNA was used and made up to a volume of 
10 μL with water. The reaction mix in Table 2.4 was used. Table 2.5 shows the general 
template used for the reactions. The annealing temperature was originally set at 55°C, but 
was decreased for subsequent PCR reactions due to lower melting temperatures of the 
primers (Table 2.2). Extension at 72°C was increased to two minutes due to the length of 
XFLM_07435 (2,604 base pairs). 
Table 2.4 - PCR reaction parameters. 
PCR Mix Volume 
10x buffer 5 μL 
dNTPs (50 mM) 1 μL 
Forward primer (100 μM) 0.2 μL 
Reverse primer (100 μM) 0.2 μL 
DNA (genomic or plasmid) ~100 ng in 10 μL 
MgSO4 (50 mM) 2 μL 
Platinum® Taq polymerase Hi fidelity 0.2 μL 
H2O 30 μL 
Total 50 μL 
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Table 2.5 - Template PCR Program 
Temperature (°C) Time (min) Cycles 
94°C (melting) 2 1 
94°C (melting) 0.75  
25 ~3°C lower than primer Tm (annealing) 0.75 
72°C (extension) 2 
72°C (extension) 2 1 
4°C As needed (<60) 1 
 
2.2.5   DNA Gel Electrophoresis 
All DNA gels were made to a concentration of 1% agarose with 1xTris-acetate-EDTA 
(TAE) buffer, diluted from a 50x TAE stock solution. The 50x TAE stock solution 
contained: 242 g Tris Base, 57.1 mL glacial acetic acid, and 100 mL 0.5 M EDTA pH 8.0, 
made up to a volume of 1 L with H2O. 
Agarose (0.5 g) was added to 50 mL TAE, which was then heated until all the agarose was 
dissolved. SYBR Safe (Invitrogen™ by Life Technologies, Carlsbad, California, USA) 
(3 μL) was added to the heated solution and mixed. PCR product (20 μL) was added to 
5-10 μL of loading buffer and run against a DNA ladder (HyperLadder I, Bioline USA Inc., 
Taunton, Massachusetts, USA) at 120 V for 20 minutes. Gels were visualised with a 
Syngene ‘Gene Genius’ gel doc (Syngene UK, Cambridge, UK) and GeneSnap software. 
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2.2.6   Ligation into Vector 
When ligating into linearised pCR2.1-TOPO vector, 2 μL of PCR product, 1 μL of vector 
(1 μL = 1 reaction), 1 μL of salt solution and 2 μL of water were incubated at room 
temperature for 20 minutes.   
For ligation of XFLM_07435 into linearised pBluescriptSK+, pET30GST or pET30ΔSE, a 
2:1 ratio of insert to plasmid was used (approximately 20 ng of insert to 10 ng of vector) 
while trying to keep the reaction volume less than 10 μL. To the combined insert and 
plasmid, 6 μL of T4 DNA ligase (DNA Ligation Kit Ver.2.1, TaKaRa Bio Inc., Otsu, Shiga, 
Japan) was added. The reaction was incubated at room temperature for 20 minutes. 
2.2.7   Transformation 
Ligated plasmid (100 ng) was added to a tube of competent cells (100 μL) on ice. 
Competent cells with no DNA added were used as a control. The cells were incubated on 
ice for 20 minutes, heat shocked for 90 seconds at 42°C, and then returned to ice for 
another two minutes. LB (200 μL) was added to the cells for recovery. The transformed 
cells were then incubated at 37°C for one hour before being plated on agar with the 
relevant antibiotic. The plate was incubated at 37°C overnight. 
2.2.8   Plasmid Extraction 
Plasmid extraction was achieved according to the protocol in the Purelink® Quick Plasmid 
Miniprep Kit (Invitrogen™ by Life Technologies, Carlsbad, California). A 5 mL pre-
culture of E. coli cells containing the desired plasmid was grown overnight at 37°C. The 
cells were centrifuged at 12,000 rpm for 10 minutes and the resulting pellet was used for 
the miniprep. Cells were first resuspended with the resuspension buffer (250 μL), then 
lysed with 250 μL of lysis buffer, at room temperature for five minutes. Precipitation buffer 
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(350 μL) was added to the lysate. The lysate was centrifuged at 12,000 rpm for 10 minutes 
to remove cell debris. The supernatant was loaded into a spin column and centrifuged at 
12,000 rpm for one minute. Wash buffer (700 μL) was applied to the spin column and 
centrifuged for one minute at 12,000 rpm. The flowthrough was discarded and the column 
was spun for one minute to remove the wash buffer. The spin column was placed in a 
recovery tube and 50 μL of H20 was added to the column. After incubation for one minute, 
the column was centrifuged at 12,000 rpm for two minutes to elute the DNA. The DNA 
concentration was measured at 280 nm using a NanoDrop Spectrophotometer ND-1000 
(Thermo Scientific, Waltham, Massachusetts, USA). Purified DNA was stored at -20°C.  
2.2.9   Restriction Digest 
For each sample to be digested, 1000 ng of DNA was required. In all digestions, 5 μL of 
10xNEBuffer #4 (500 mM potassium acetate, 200 mM Tris-acetate, 100 mM magnesium 
acetate, 10 mM DTT, pH 7.9), 1 μL of each restriction enzyme (20,000 U/mL), and 0.2 μL 
of BSA (10 mg/mL) were added. The reaction mix was brought up to 50 μL with water. 
The digest was incubated at 37°C for one-three hours. The digested samples (50 μL) were 
then loaded onto an agarose DNA gel and run for 20 minutes. The DNA bands were 
visualised using a DarkReader transilluminator. DNA bands were cut out of the agarose gel 
and placed in 2 mL eppendorf tubes. 
2.2.10   DNA Purification from Agarose Gel 
DNA was purified from agarose gel using an Agarose Gel DNA Extraction kit (Roche, 
Indiana, Indianapolis, USA) and a small benchtop centrifuge. Agarose solubilisation buffer 
(500 μL) was added to a piece of agarose gel containing the DNA of interest (from section 
2.2.9). This was heated to 55°C for five minutes to melt the agarose. 10 μL of silica matrix 
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was added to bind the DNA. It was mixed thoroughly and incubated at room temperature 
for 10 minutes. The silica was pelleted (12,000 rpm for 30 seconds) and the supernatant 
discarded carefully so as not to remove any silica. 500 μL of nucleic acid binding buffer 
was added and mixed with the silica. The mixture was centrifuged, and the supernatant 
discarded. 500 μL of washing buffer was added to the silica and mixed, and then the 
sample was centrifuged for one minute. All of the supernatant liquid was then removed 
using a pipette. The silica was left to dry for a few minutes. The silica was then 
resuspended in 10 μL of nuclease-free water and vortexed every two-three minutes for 
10 minutes. Centrifugation at 12,000 rpm for 30 seconds pelleted the silica, and the 
supernatant containing the purified DNA was removed. The concentration of DNA was 
measured using the Nano Drop. 
2.2.11   DNA Sequencing 
Sequencing of the XFLM_07435 gene was performed in the sequencing suite at the 
University of Canterbury. Three primers were used to sequence the entire gene (2.2.1.4), as 
XFLM_07435 is a long gene (2,604 base pairs). The primers were used at a concentration 
of 3.2 μM. Miniprepped dsDNA plasmid was provided at a concentration of 50 ng/μL, with 
6-7 μL given per primer used in sequencing (e.g. 3 primers = 20 μL).  
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2.3   Protein Biochemistry 
2.3.1   Pre-cultures 
To make pre-cultures, 5 μL of relevant antibiotic and one colony or a stab from a frozen 
glycerol stock were added to 5 mL of autoclaved LB. The pre-culture was incubated at 
37°C overnight on a shaker. 
2.3.2   Glycerol Stocks 
A 5 mL pre-culture was incubated overnight at 37°C. 1 mL aliquots were pipetted into 
2 mL eppendorf tubes. 500 μL of 50% glycerol was added to each aliquot of culture. The 
cells were then snap frozen using liquid nitrogen and stored at -80°C.  
2.3.3   Protein Expression 
A pre-culture (2-5 mL) was added to 500 mL of autoclaved LB containing the appropriate 
concentration of antibiotic. These cultures were placed in a Minitron incubator at 37°C and 
grown to an OD600 of 0.4-0.6 for cells transformed with the pET30ΔSE-HisXF vector or to 
an OD600 of 0.7-0.9 for cells transformed with SDH-pET16b. Cultures were then incubated 
at 26°C for 30 minutes to cool down before inducing with IPTG. Cells containing 
XFLM_07435 were induced with 0.2 mM IPTG. Cells containing SDH were induced with 
1 mM IPTG. The cells were then incubated overnight at 26°C to allow expression. Cells 
were harvested by centrifugation at 8,000 rpm for 15 minutes. Cell pellets were stored at 
-20°C or put on ice and resuspended with lysis buffer. 
2.3.3.1   Expression Trials 
Expression trials were conducted using small scale cultures (20-100 mL LB). Cells 
transformed with a vector containing the XFLM_07435 insert (pBluescript-XF, 
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pET30ΔSE-XF, pET30ΔSE-HisXF, or pET30GST-XF) were plated on agar containing the 
relevant antibiotic(s). The agar plate was incubated overnight at 37°C. The next day, 5 mL 
pre-cultures were made from individual colonies. These pre-cultures were incubated at 
37°C overnight. The next day, each pre-culture was added to a flask of autoclave LB (20-
100 mL), with the relevant antibiotic(s), and the culture was incubated at 37°C until the 
OD600 reached 0.4-0.6. The cultures were then induced with 1 mM IPTG (final 
concentration) and expressed overnight at 37°C. After samples were taken to test for 
expression or solubility the remainder of the culture was centrifuged at 8,000 rpm for 
10 minutes at 4°C and the media removed. Cell pellets were stored at -20°C. 
2.3.3.2   Testing for over-expression 
Samples (20 μL) were taken pre-induction, one hour post-induction, four hours post-
induction and 16 hours post-induction. These samples were analysed by SDS-PAGE 
(Section 2.3.4) for over-expression. The remainder of the cultures were centrifuged at 
8,000 rpm, then stored at -20°C to be used for subsequent solubility tests. 
2.3.3.3   Testing for solubility 
Larger samples were taken (1 mL-20 mL) pre-induction, one hour post-induction, four 
hours post-induction, and 16 hours post-induction. These samples were centrifuged at 
8,000 rpm and the media removed. The cell pellets were resuspended in buffer: 1 mL of 
culture was resuspended in 100 μL of buffer. The samples resuspended in 100-200 μL 
buffer was lysed using a sonicating bath for 30 second intervals for a total of two minutes 
of sonicating. Samples resuspended in 200 μL or more of buffer were lysed using the 
Stepped Titanium Microtip (3.9 mm diameter) of the Sonic Ruptor 400 Ultrasonic 
Homogenizer (Omni International Inc., Kennesaw, Georgia, USA). Sonication was carried 
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out on ice for 5 second intervals for a total of two minutes. Lysed samples were then 
centrifuged for 10 minutes at 8,000 rpm and 4°C. The supernatants were analysed by SDS-
PAGE (Section 2.3.4). 
2.3.4   Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
Bolt® Pre-cast 4-12% Bis-Tris Plus 10 well or 15 well electrophoresis gels were supplied 
by Novex (Novex® by Life Technologies™, Carlsbad, California, USA). Sodium Dodecyl 
Sulphate Polyacrylamide Gel Electrophoresis (SDS PAGE) was carried out in a Bolt™ 
Mini Gel Tank (Novex® by Life Technologies™, Carlsbad, California, USA) using a 
BioRad PowerPac machine with 1x MES SDS buffer (Diluted from 20x MES SDS Buffer, 
Invitrogen™ by Life Technologies, Carlsbad, California, USA). Novex® Sharp Pre-stained 
Protein Standard (Novex® by Life Technologies, Carlsbad, California, USA) was used as a 
ladder/reference by loading 5 μL into one of the wells of the gel. Sample reducing dye 
(25 μL Bolt™ LDS Sample buffer 4x, 10 μL Bolt™ reducing agent 10x, and 15 μL H2O) 
was added to the samples at a ratio of 1:1. Samples were then boiled at 90°C in an 
Accublock Digital Dry Bath (LabNet International Inc., Edison, New Jersey, USA) for two 
minutes before loading them into the gel. Boiled samples were stored at -20°C if not used 
immediately. The gels were run at 165 V for 35 minutes. Gels were stained with 
Coomassie Blue stain (1 g Coomassie, 450 mL methanol, 450 mL water, 100 mL acetic 
acid) for 20 minutes and destained using Coomassie destain (450 mL methanol, 450 mL 
water, 100 mL acetic acid) until the gel was destained sufficiently to photograph the gel 
using the Syngene ‘Gene Genius’ gel doc (Syngene UK, Cambridge, UK). 
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2.3.5   Cell Lysis 
Cell pellets from 1 L cultures containing AK:DapDc were resuspended in 10 mL lysis 
buffer I (20 mM Tris pH 8.5, 200 mM NaCl, 1 mM DTT, 5 μM PLP) and lysed using a 
Microfluidics M-110P homogenizer (Microfluidics USA, Westwood, Massachusetts, 
USA). The machine was first washed with H2O to remove all methanol from the system 
and then equilibrated with the cell lysis buffer. The resuspended cells were run through the 
machine two-three times to ensure complete lysis, according to the manual (Microfluidics 
M-110P series). The lysate was then centrifuged for 10 minutes at 9,000 rpm. 
Cell pellets containing ScSDH were resuspended in lysis buffer II (200 mM Tris pH 8.0) 
and lysed using a Hielscher UPS200 S ultrasonic processor, according to Xu et al. (2006)
1
. 
The sonicator was set to a cycle of 0.3 second pulse followed by a 0.7 second rest at 40% 
power for two minutes. The lysate was then centrifuged at 9,000 rpm for 10 minutes. 
2.3.6   Column Chromatography 
2.3.6.1   HisTrap Chromatography of AK:DapDc 
A 5 mL pre-packed HiTrap FF HisTrap column (GE Healthcare Life Sciences, Uppsala, 
Sweden) was used for AK:DapDc purification. The HiTrap FF column was controlled by 
an ÄKTAFPLC (GE Healthcare, Uppsala, Sweden) and fractionation was carried out by 
the same machine. The 5 mL column was pre-equilibrated with five column volumes of 
lysis buffer I (See below). The lysed and centrifuged crude fraction (40-80 mL) was loaded 
onto the column at 2 mL/minute. Once the entire sample was loaded, the column was 
washed with 40 mL of lysis buffer I at 2.5 mL/minute. A gradient of 0-100% of buffer B 
(Table 2.6) over 30 minutes was initiated. The ÄKTA-FPLC was set to run for an 
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additional 10 minutes at 100% buffer B. Fractions of 1.8 mL were collected throughout the 
purification, beginning as the centrifuged crude fraction was loaded onto the column. 
Table 2.6 - Purification buffers. 
Buffer Composition 
A Lysis buffer I (20 mM Tris pH 8.5, 200 mM NaCl, 1 mM DTT, 5 μM PLP) 
B Lysis buffer I + 500 mM imidazole 
 
2.3.6.2   His-Trap Chromatography of ScSDH 
His-Trap chromatography was carried out using a 5 mL disposable gravity flow column 
(Thermo Fisher Scientific Inc., Rockford, Illinois, USA) and 1 mL of HisPur™ Cobalt 
Resin (Thermo Fisher Scientific Inc., Rockford, Illinois, USA) for SDH purification. The 
HisPur Cobalt column was operated on the bench top and 1 mL fractions were collected in 
1.7 mL eppendorf tubes. The 1 mL column was pre-equilibrated with 10 mL of lysis buffer 
II (200 mM Tris pH 8.0). The lysed and centrifuged crude fraction (20-40 mL) was loaded 
onto the column using a syringe at approximately 3 mL/minute. The flowthrough was 
collected in a 50 mL Falcon tube. The column was then washed with 20 mL of lysis buffer 
II, followed by 20 mL of lysis buffer II + 20 mM imidazole. The flowthrough from both 
washes was also collected in a 50 mL Falcon tube. SDH was eluted from the column using 
20 mL of lysis buffer II + 150 mM imidazole. Elution fractions of 1 mL were collected in 
1.7 mL Eppendorf tubes. Samples (10 μL) of the lysed cells, crude fraction, flowthrough, 
both washes, and elution fractions were analysed using SDS-PAGE. 
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2.3.6.3   Size Exclusion Chromatography (SEC) 
SEC was carried out using a HiLoad 16/200 Superdex 200 pg (GE Healthcare Life 
Sciences, Uppsala, Sweden) column with a volume of 120 mL. This column was also 
controlled by an ÄKTA and fractions of 1 mL were collected by the same machine 
throughout the purification. The column was equilibrated with 400 mL of SEC buffer 
(20 mM Tris pH 7.5, 200 mM NaCl, 1 mM DTT, 5 μM PLP). The protein sample from 
His-Trap chromatography was concentrated to 2 mL using a Vivaspin® 6 30,000 Da 
MWCO spin concentrator (Sartorius, Göttingen, Germany). The sample was loaded into a 
2 mL loop and loaded onto the column at a rate of 1 mL/minute. Once the sample was 
loaded, 120 mL of SEC buffer was run through the column at 0.5 mL/minute. Fractions of 
the elution peaks were analysed by SDS-PAGE. 
2.3.7   Kinetic Analysis 
2.3.7.1   Stock Solutions 
Tris buffer (pH 8.0) was made as a stock solution of 1 M in H2O. DAP is not very soluble, 
so it was dissolved in equimolar Tris, that is 200 mM DAP was dissolved in 200 mM Tris 
pH 8.0. Lysine was dissolved in H2O to give a stock solution of 500 mM. PLP stock 
solution was made up in H2O to a concentration of 5 mM. α-ketoglutarate (α-KG) is very 
acidic and was made as a stock solution of 500 mM by dissolving the α-KG in half the 
final stock volume, then using 5 M NaOH to increase the pH to 8.0, before making up the 
volume to the final stock volume. The SDH stock solution concentration was 1.5 mg/mL 
and was achieved by concentrating the SDH elution fractions from HisTrap 
chromatography using a Vivaspin 6 10,000 Da MWCO spin concentrator (Sartorius, 
Göttingen, Germany). 
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2.3.7.2   Equipment and Software 
Kinetic analysis was carried out using a CARY 100 Bio UV-Visible Spectrophotometer 
(Agilent Technologies, Santa Clara, California, USA), using the CARY Kinetics software.  
2.3.7.3   Assay reaction mix 
The SDH activity assay was carried out with the assay mix listed in Table 2.7. The total 
volume of the assay mix was actually 1000 μL minus the volume of SDH to be used in the 
assay, so that the total volume of every assay is 1000 μL.  
Table 2.7 - The saccharopine dehydrogenase assay reaction mix. 
Chemical MW Initial (mM) Volume (μL) Final (mM) 
Tris pH 8.0 121.14 1000 135 135 
DAP/Tris 190.2 200/200 200 40/40 
Lysine 182.6 500 50 25 
PLP 247.142 5 20 0.1 
α-KG/Tris 146.11 500/500 50 25/25 
NADH (Na2) 709.4 8 20 0.16 
Water   up to 1000  
Total   1000  
 
2.3.7.4   SDH concentration vs. rate of reaction assay 
The assay was monitored at 340 nm for two minutes at 37°C. The instrument was blanked 
with water. The initial slope of the reaction was estimated using the CARY Kinetics 
software. The reaction mix was set up as per Section 2.3.7.3, using an SDH stock of 1.5 
mg/mL (34.1 μM). The final concentration of SDH in the 1 mL reaction was increased 
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from 0.0335 μM to 1.5 μM, with the volume of water added adjusted so that the final 
reaction volume was 1 mL. The SDH concentrations measured were: 0.0335 μM, 
0.0675 μM, 0.125 μM, 0.25 μM, 0.5 μM, 1.0 μM, 1.5 μM. No measurements were taken 
above 1.5 μM SDH as the initial rate became too difficult to measure and calculate 
accurately. Three replicates of each concentration were measured. These replicates agreed 
within 10% error. 
2.3.7.5   Lysine concentration vs. rate of reaction assay 
The assay was monitored at 340 nm for two minutes at 37°C. The instrument was blanked 
with water. The initial slope of the reaction was estimated using the CARY Kinetics 
software. The reaction mix was set up as per Section 2.3.7.3, using an SDH stock of 
1.5 mg/mL (34.1 μM) and the final concentration of SDH in the reaction was 0.25 μM. The 
concentration of lysine ranged from 1-100 mM (1 mM, 2 mM, 5 mM, 10 mM, 15 mM, 
25 mM, 50 mM, 100 mM) while keeping the α-ketoglutarate(α-KG) concentration at 
25 mM. The volume of water added was adjusted so that the final reaction volume was 
1 mL. 
2.3.7.6   Assaying for AK:DapDc activity 
The assay was monitored at 340 nm for two minutes at 37°C. The instrument was blanked 
with water. The initial slope of the reaction was estimated using the CARY Kinetics 
software. The reaction mix was set up as per Section 2.3.7.3, using an SDH stock of 
1.5 mg/mL (34.1 μM) and a final concentration of SDH in the reaction of 3 μM. Lysine 
was excluded from the reaction mix as this assay tests the ability of AK:DapDc to convert 
meso-diaminopimelate into lysine. The AK:DapDc stocks used were 1 mg/mL (10.25 μM). 
The final concentration of AK:DapDc used was 200 nM. For this assay, the reaction mix 
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was equilibrated to 37°C, then the SDH enzyme was added and mixed using a pipette. The 
absorbance was monitored for a few seconds to check that the SDH was not reacting with 
the substrates present. The AK:DapDc was then added and mixed quickly with a pipette. 
The absorbance was monitored for two minutes. 
2.4   Biophysical Techniques 
2.4.1   Differential Scanning Fluorimetry (DSF) 
DSF was carried out on a Bio-Rad iQ5 RT-PCR machine (Bio-Rad Laboratories, Hercules, 
California, USA), using Bio-Rad iQ5 software. 96 well clear pcr plates and clear seals 
were used. The fluorescence of SYPRO Orange was measured from 20°C-100°C, in steps 
of 0.5°C. The temperature was increased for 10 seconds and held at that temperature for 
10 seconds, taking measurements at each temperature.  
Buffer optimisation using DSF was carried out using a modified Seabrook & Newman 
protocol 
2
, with the sample volume changed from 20 μL to 25 μL (0.3 μL of 1:10 SYPRO 
Orange, 2 μL protein sample, 22.7 μL buffer). See Appendix I for the modified table of 
buffers used. The 96 well plate was set up with the buffers, then protein sample, then 
SYPRO solution. Before sealing the plate with a clear seal the samples were degassed for 
5 minutes. 
For aggregation tests, a photo of the 96 well plate was taken to show the fluorescence 
detected at the start of the run. Buffer controls and positive controls (aggregated protein) 
were used. 
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2.4.2   Buffer Exchange 
Buffer exchange of AK:DapDc samples was performed using a 5 mL GE HiTrap desalting 
column (GE Healthcare Life Sciences, Uppsala, Sweden) according to the GE Healthcare 
manual, with a syringe. The column was equilibrated with 25 mL of the final protein 
buffer. 1 mL of protein sample was applied to the column with a syringe. Buffer (0.5 mL) 
was added to the column to bring the total sample volume to 1.5 mL (the column’s void 
volume). Additional buffer was applied to the column and the eluted buffer was collected 
until three 1 mL elution fractions had been eluted. A NanoDrop, measuring at 260 nm and 
280 nm, was used to determine where the protein was eluted. The column was then washed 
and stored in 20% ethanol. 
2.4.3   Circular Dichroism (CD) 
Circular dichroism was carried out in a JASCO J-815 CD Spectrometer (JASCO 
International Co. Ltd, Hachioji, Tokyo, Japan) using a 2 mm cuvette. Scans were run from 
180-260 nm (far-UV) at a pitch of 1 nm, with replicates of three. The speed was set to 
100 nm/min. The temperature was set at 20°C. First, buffer checks were carried out to 
determine what concentration of Tris buffer and additives were acceptable to use for CD 
measurements. Samples were equilibrated at 20°C for five minutes. Then measurements 
were taken from 180-260 nm. 
2.4.4   Analytical Ultracentrifugation 
Analytical ultracentrifugation to measure sedimentation velocity was performed on a 
Beckman Coulter Proteome Lab XL-I (Beckman Coulter, Brea, California, USA) 
ultracentrifuge, with an An-50 Ti 8-hole analytical rotor (Beckman Coulter), and using 
double sector cells with quartz windows. The density and viscosity of buffers was 
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calculated using Sednterp (http://sednterp.unh.edu/). Data analysis was performed using 
sedfit 
3
. 
A 400 μL reference sample of buffer (SEC buffer) was placed in the reference cell. The 
sample volume was 380 μL. Three different concentrations of protein sample were run 
(0.1 mg/mL, 0.4 mg/mL, and 0.8 mg/mL). Initial wavelength (200-300 nm) and radial 
scans were conducted at 3,000 rpm to determine the best wavelength and radial position 
for the measurements. Runs were then carried out at 40,000 or 45,000 rpm, at a 
temperature of 20°C. 
2.4.4.1   AK:DapDc sample purified using anion exchange and SEC 
AK:DapDc (1 mg/mL) was divided into three 380 μL samples of 0.1 mg/mL, 0.4 mgmL 
and 0.8 mg/mL, adding SEC buffer to each sample to dilute them to the appropriate 
concentration. The concentration was measured using a spectrophotometer at 280 nm. Each 
of these samples (380 μL) was loaded into a double sector cell, with a buffer reference 
(SEC buffer) of 400 μL. The samples were spun at 3,000rpm, measuring at 200-300 nm to 
calculate the appropriate wavelength and radial position to take further measurements at. 
The sample was then run at 40,000 rpm, taking 250 scans at 290 nm and a radial position 
of 5.8-7.3 mm. 
2.4.4.2   AK:DapDc sample purified by His-Trap chromatography and SEC 
The elution peaks two and three containing AK:DapDc purified by His-Trap 
chromatography and SEC were pooled separately and concentrated to 1 mg/mL. Peak two 
was divided into three 380 μL samples of 1 mg/mL, 0.4 mg/mL, and 0.8 mg/mL, adding 
SEC buffer to each sample to dilute them to the appropriate concentration. The protein 
concentration was measured using a spectrophotometer at 280 nm. Each 380 μL sample 
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was loaded into a double sector cell, with a buffer reference (SEC buffer) of 400 μL. The 
samples were spun at 3,000 rpm, measuring at 200-300 nm to calculate the appropriate 
wavelength and radial position to take further measurements at. The samples were then run 
at 40,000 rpm, taking 150 scans at 288 nm and a radial position of 5.8-7.3 mm.  
Peak three was divided into two samples of 0.1 mg/mL and 0.8 mg/mL, adding SEC buffer 
to each sample to dilute them to the appropriate concentration. The protein concentration 
was measured using a spectrophotometer at 280 nm. Each 380 μL sample was loaded into 
a double sector cell, with a buffer reference (SEC buffer) of 400 μL. The samples were 
spun at 3,000 rpm, measuring at 200-300 nm to calculate the appropriate wavelength and 
radial position to take further measurements at. The samples were then run at 45,000 rpm, 
taking 150 scans at 285 nm and a radial position of 5.8-7.3 mm.  
2.4.5   Crystal Trays 
Protein samples (AK:DapDc) were concentrated to 10 mg/mL using a Vivaspin 6 
30,000 Da MWCO spin concentrator (Sartorius AG, Göttingen, Germany). 
Morpheus™ (MD1-47), JCSG-plus™ HT-96 (MD1-36), PACT premier™ HT-96 (MD1-
40), and Clear Strategy Screen™ I HT-96 (MD1-31) crystal screens from Molecular 
Dimensions (Molecular Dimensions Limited, Suffolk, UK) were used in this study. 
Crystallisation buffer from these screens (300 μL) was pipetted into the wells of a 96 well 
sitting drop plate using a multi-channel pipette. Two plates of each screen were pipetted 
out so that two crystallisation temperatures could be trialled- 5°C and 20°C. A TTP 
LabTech Mosquito (TTP Labtech Ltd, Melbourn, Hertfordshire, UK) was used to pipette 
300 nL of concentrated protein and 300 nL of crystallisation buffer onto the sitting drop 
well/plate. The trays were covered with clear seals. The plates were incubated at 5°C or 
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20°C for several weeks to see if crystals would form. Photos of the crystal trials were taken 
with a microscope camera. 
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3.   Cloning, Expression and Purification of AK:DapDc 
3.1   Introduction 
Xylella fastidiosa research has primarily focused on its biology to establish how the 
bacterium infects and affects plants
1-5
, which plants it affects
6-9
, how it affects the insect 
vector, and which insects are vectors
10, 11
. Metabolic pathways such as carbohydrate 
metabolism have been investigated
12
, but no research has focused on essential biosynthetic 
enzymes. Genome annotation of X. fastidiosa
13
 suggested that a number of genes in 
biosynthetic pathways, such as amino acid biosynthesis, are missing
14
. Investigating the 
functionality of the predicted aspartate kinase:diaminopimelate decarboxylase, by first 
over-expressing and purifying it, could indicate if X. fastidiosa can synthesise lysine.  
A bifunctional biosynthetic enzyme such as AK:DapDc, unique to a small family of 
bacteria (Xanthomonadaceae), might be a useful pesticide target, as an inhibitor could be 
highly specific to the bifunctional bacterial enzyme and not affect the corresponding 
monofunctional plant enzymes. However, AK:DapDc needs to be experimentally 
characterised first. 
Characterisation of more bifunctional enzymes, especially those that catalyse non-
consecutive reactions, will add to our knowledge base of the mechanisms of action of 
bifunctional enzymes. It may also help us to understand why these enzymes evolve and if 
they are more advantageous than multi-enzyme complexes. The evolutionary significance 
of enzymes such as AK:DapDc is that they may provide rapid regulation of pathways and 
colocalization of enzymes from the same pathway
15
. 
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Many aspartokinases have been purified and crystallised, with the aspartokinases of E.coli 
being the most studied
16
. Aspartokinases I (bifunctional with HSDH I) and III originating 
from microorganisms such as Escherichia coli (BL21DE3, K12)
17, Anheuser Baker’s 
yeast
18
, Streptomyces claviguligerus
19
, Mycobacterium tuberculosis
20
, Amycolatopsis 
mediterranei U32
21
, Bacillus subtilis
22
, and Synechocystis species
23
 have been purified. 
These studies
24
 used endogenous genes to synthesise the protein. Aspartate kinase was 
purified by ammonium sulphate precipitation, ion exchange chromatography, and size 
exclusion
22, 25
. More recent papers replace ammonium sulphate precipitations with His-
Trap chromatography and hydrophobic interaction chromatography
21
, and use vectors to 
over-express recombinant genes in E.coli
20
. 
Diaminopimelate decarboxylase (DapDc) has been expressed and purified via several 
methods
26, 27
. Endogenous DapDc has been purified from microorganisms such as E. coli
26
, 
Micrococcus glutamicus
28
, Corynebacterium glutamicum
29
, and Bacillus subtilis
30
. DapDc 
was purified by sonication/French press followed by ammonium sulphate precipitation, 
then size exclusion, anion exchange or hydroxyapatite chromatography. Recombinant 
DapDc from organisms such as E. coli
31
, Helicobacter pylori
32
, and Mycobacterium 
tuberculosis
33
 have been over-expressed in E. coli and purified using Ni
2+
 His-Trap 
chromatography followed by size exclusion. 
The functions of AK:DapDc are putative and it has never been experimentally 
characterized before
13
. Genome sequencing and annotation using BLAST
34
 predict that 
AK:DapDc is one gene, containing the conserved domain features for AK and DapDc. In 
this study, information from the literature about the purification of the individual 
monofunctional forms of AK and DapDc has been used to attempt to find the best 
conditions with which to clone, express and purify the bifunctional AK:DapDc. 
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3.2   Cloning XFLM_07435 into an Expression Vector 
The XFLM_07435 gene was amplified via polymerase chain reaction (PCR) from the 
genomic X. fastidiosa DNA to include the addition of the SacI restriction site at the 5’ end 
of the gene and the HindIII restriction site at the 3’ end of the gene. PCR was carried out 
according to Section 2.2.1 using primers oRD53 (5’ end) and oRD54 (3’ end). This 
generated a 2604 bp sized DNA fragment, which gave a single band on a DNA agarose gel 
carried out according to Section 2.2.5 (Figure 3.1). 
 
Figure 3.1 - PCR amplification of XFLM_07435. 
 
Ligation of the PCR product into pCR2.1TOPO according to Section 2.2.6, followed by 
transformation of the ligation product into E. coli XL1 Blue cells (2.2.7), and plating on 
agar + Amp resulted in many transformed colonies. After pre-culturing several of the 
transformed colonies (2.3.1) and purifying the pCR2.1TOPO-XF plasmid from the cells 
(2.2.8), pCR2.1TOPO-XF and empty pET30ΔSE expression vector were subject to a 
double restriction digest using the SacI and HindIII restrictions enzymes (2.2.9). 
pCR2.1TOPO-XF was digested to excise the XFLM_07435 gene from the plasmid ready 
for ligation into the expression vector pET30ΔSE. Both digested plasmids were run on an 
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agarose gel (Figure 3.2) so that the XFLM_07435 insert and the restricted pET30ΔSE 
could be purified according to Section 2.2.10 (pCR2.1TOPO + XFLM_07435 = 6,500 bp). 
Additional pET30ΔSE was digested with NdeI and HindIII to give a linearised vector with 
no His-Tag. pBluescriptSK+ and pET30GST were linearised by double digestion with SacI 
and HindIII restriction enzymes. 
 
Figure 3.2 - DNA gel of the double digest of pCR2.1TOPO-XF to give pCR2.1TOPO 
and XFLM_07435 insert with 5’ SacI and 3’ HindIII restriction sites. 
 
The linearised pET30ΔSE vector and XFLM_07435, pBluescript SK+ and XFLM_07435, 
and pET30GST and XFLM_07435 were ligated according to Section 2.2.6 to give 
pET30ΔSE-XF, pET30ΔSE-HisXF, pBluescript-XF and pET30GST-XF. E. coli XL1 Blue 
cells were transformed with the ligated plasmids and incubated on LB-agar plates. Several 
resulting colonies from each transformation were pre-cultured, and plasmid DNA purified 
from the cells. This purified plasmid was sequenced using T7 vector primers, and this 
proved that the XFLM_07435 gene had been successfully inserted into the vector in each 
case. The pET30GST-XF construct could not be sequenced properly. 
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3.3   Expression 
Over-expression of AK:DapDc was achieved after many expression trials (see section 
2.3.3). E. coli BL21 DE3 cells were transformed with one of the purified vectors with 
XFLM_07435 inserts (pBluescript-XF, pET30GST-XF, pET30ΔSE-HisXF, or pET30ΔSE-
XF). Small scale expression was trialled at 37°C. Cells transformed with pBluescript-XF 
did not over-express AK:DapDc, and despite sequencing results the cells transformed with 
pET30GST-XF only over-expressed the GST tag. The cells transformed with pET30ΔSE-
HisXF or pET30ΔSE-XF over-expressed AK:DapDc at 37°C. Further expression trials 
were conducted with only the pET30ΔSE constructs.  
The pET30ΔSE-HisXF was transformed into both E. coli BL21 DE3 and BL21 DE3 
Rosetta cells and expression was carried out overnight at 37°C to see if the rare tRNA 
codons encoded on the pRARE plasmid in Rosetta cells increased the solubility of 
AK:DapDc. There was no noticeable difference, so all subsequent expression trials were 
conducted using E. coli BL21 DE3 cells. 
Several growth temperatures (4°C, 26°C, and 37°C) were trialled to determine the 
conditions best conducive to soluble protein expression. Expression at 26°C gave the best 
AK:DapDc solubility (using the steps in section 2.3.3), so all subsequent trials were 
performed at 26°C. Low isopropyl β-D-1-thiogalactopyranoside (IPTG) concentration 
(0.1 mM) and expression overnight at 4°C, as well as high IPTG concentration (2 mM) and 
expression for two hours at 37°C were tested. These conditions did not prevent AK:DapDc 
aggregation. Varying the IPTG concentration (0.1–1 mM) did not affect AK:DapDc 
solubility.  
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Supplementation of the LB media did not noticeably affect AK:DapDc expression or 
solubility. Glucose (1%) was added to both the pre-cultures and larger cultures to prevent 
leaky expression and slow down AK:DapDc expression. The cofactor for the DapDc 
domain (pyridoxal phosphate - PLP) was added to the media upon induction with IPTG to 
determine if an increase in PLP would help stabilize the DapDc domain. It remains unclear 
if this helps with solubility. 
AK:DapDc was over-expressed in E. coli BL21 cells (Figure 3.3). Cultures of E. coli BL21 
DE3 cells transformed with pET30ΔSE-HisXF were incubated at 37°C until the O.D600 
reached 0.4–0.6, and then the cultures were incubated at 26°C for 30 minutes to cool the 
cultures before inducing with 0.4 mM IPTG. Cultures were incubated overnight at 26°C. 
Samples of un-induced culture, one hour post-induction, four hours post-induction, and 
overnight were taken to check for protein expression. These samples were run on an SDS-
PAGE gel (Figure 3.3). The cultures were harvested by centrifugation at 8,000 rpm for 10 
minutes. Cell pellets were stored at -20°C or resuspended immediately in lysis buffer, at 
4°C. 
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Figure 3.3 - SDS-PAGE of AK:DapDc over-expression. 
3.4   Purification 
Purification of AK:DapDc from E. coli BL21 DE3 cells was achieved after many 
purification trials, investigating different buffer systems as well as methods of purification. 
Initial AK:DapDc solubility trials were conducted using PBS pH 7.0. Detergents of varying 
concentrations (0.1–1% Triton-X 100 and 0.1–1% CHAPS) were added to PBS buffer to 
aid in solubility. Concentrations of 0.5–1% Triton-X 100 appeared to increase the solubility 
of His-tagged AK:DapDc. The presence of NaCl or MgCl2 in a lysis buffer was trialled. 
NaCl gave an increase in solubility while MgCl2 showed no improvement. The addition of 
PLP or lysine showed no increase in AK:DapDc solubility.  
His-Trap purification was first attempted in PBS buffer pH 7.0 on a gravity flow column 
using a hybrid batch/gravity flow method. AK:DapDc bound to the beads, but would not 
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elute with 200 nM or 500 mM imidazole, or thrombin cleavage of the His-Tag (Figure 3.4). 
The presence of Triton-X 100 in the buffers did not change this. 
 
Figure 3.4 - SDS-PAGE analysis of elution from His-Trap column after cleavage of 
the His-tag by thrombin. The bead fraction was taken after thrombin incubation 
overnight and subsequent elution. 
 
Anion exchange chromatography was trialled with both His-tagged and untagged 
AK:DapDc. Most of the AK:DapDc protein did not bind to the column and was present in 
the flowthrough, using PBS buffer. Small amounts of AK:DapDc bound to the column at 
pH 8.5 using Tris buffer. The flowthrough was pooled, concentrated, and run through a size 
exclusion column. The sample did not separate and was very contaminated with other 
proteins (Figure 3.5). Different buffering conditions were needed to improve the quality of 
purified AK:DapDc samples. 
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Figure 3.5 - SDS-PAGE analysis of size exclusion. There is no separation of the 
proteins by size, indicating aggregation. 
 
Fractions of the AEC flowthrough and the size exclusion (SEC) were concentrated and 
analysed by SDS-PAGE. Both samples were hard spun to remove aggregates. Both spun 
and un-spun samples were run with and without reducing agent to determine the presence 
of aggregates or soluble aggregates of AK:DapDc (Figure 3.6). This gel highlights the 
difference in oligomeric state of AK:DapDc in reducing and non-reducing conditions. The 
reduced samples show a thicker band of AK:DapDc at 97 kDa, whereas the non-reduced 
samples have a thinner band at 97 kDa and a number of bands at 200 kDa and higher. 
These larger proteins are predicted to be AK:DapDc interacting to form higher order 
structures and aggregates. These results indicated that adding a reducing agent to the 
purification buffers would aid in preventing aggregation of AK:DapDc. 
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Figure 3.6 - SDS-PAGE analysis of anion exchange and size exclusion 
chromatography peaks, showing the presence of higher order structures (aggregates) 
in the non-reduced samples. hs = hard spun. 
 
Differential scanning fluorimetry (DSF) was used to screen buffers and salt concentrations 
(Table 3.1) according to Seabrook and Newman (2013)
35
 with some modifications 
(Appendix I). The effect of six different buffers in the pH range 4.0-9.0 indicated that a pH 
less than 6.0 was denaturing, pH 6.0 was not denaturing but gave a much lower melting 
temperature than pH 7.0-8.0The buffers which gave the highest melting temperatures were 
citrate pH 6 500 mM NaCl, sodium phosphate pH 7 500 mM NaCl, and Tris pH 7 500mM 
NaCl. A high salt concentration of 500 mM aided in stability. 
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Table 3.1 - DSF melting temperatures of AK:DapDc in various buffer systems. The 
buffers that confer the greatest stability are highlighted in red. 
Buffer  pH  Peak 1  Peak 2  
Sodium acetate  4  -  -  
Sodium acetate  5  38  52  
MES  6  48  59/61  
Citrate  4  -  -  
Citrate  5  39/40  50/51  
Citrate  6  52  62  
Sodium phosphate  6  51  62  
Sodium phosphate  7  52/53  61  
Bis-Tris propane  7  51  61  
Bis-Tris propane  8  51  60/61  
Bis-Tris propane  9  49  61  
Tris  7  51/52  64  
Tris  8  50/52  63  
 
Taking into account the buffers that DSF indicated to be stabilising, and the effect of a 
reducing agent on aggregation (Figure 3.6), a buffer system consisting of 20 mM Tris pH 
8.5, 200 mM NaCl, 1 mM dithiothreitol, and 5 μM PLP was trialled for use in His-Trap 
chromatography. This resulted in a successful His-Trap purification of AK:DapDc, which 
bound to the column and eluted at 43%B (215 mM imidazole). Samples of the soluble 
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fraction, flowthrough, wash, and peaks were run on a gel against the Novex Pre-stained 
Protein Standard (Figure 3.7). 
 
Figure 3.7 - SDS-PAGE analysis of His-Trap chromatography of AK:DapDc. 
 
The His-Trap elution fractions that contained AK:DapDc were concentrated, using a 
Vivaspin (Sartorius) 6 mL spin concentrator with a 30 kDa cut off, to approximately 2 mL. 
The sample was loaded onto a 120 mL HiLoad 16/200 Superdex 200 pg (GE Life 
Sciences) column that was pre-equilibrated with 400 mL of SEC buffer (20 mM Tris pH 
7.5, 200 mM NaCl, 5 μM PLP, 1 mM DTT). The sample was loaded onto the column at 0.5 
mL/minute. SEC buffer (120 mL) was then run through the column at 0.5 mL/minute. 
Fractions of 1mL were collected. The protein eluted in multiple peaks (Figure 3.9). 
Samples of the concentrated protein from His-Trap and the peaks from size exclusion were 
run on a gel (Figure 3.8). 
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Figure 3.8 - SDS-PAGE analysis of size exclusion. Lanes 4-6: Peak one of size 
exclusion. Lanes 7-9: Peak two of size exclusion. Lanes 10-12: Peak three of size 
exclusion. 
 
Lane three of Figure 3.8 shows a sample of the concentrated His-Trap elution peak. Lanes 
4-6 are fractions of the first size exclusion elution peak (at approximately 40-50 mL, 
Figure 3.9), this peak is the most pure but because the protein eluted within the void 
volume of the column it is predicted to contain aggregates. Lanes 7-9 are fractions from the 
second elution peak (from approximately 50-60 mL). Lanes 10-12 are fractions from the 
third elution peak (approximately 65-75 mL). Peaks two and three were used in further 
characterisation techniques. 
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Figure 3.9. Chromatogram of the size exclusion chromatography of AK:DapDc. 
 
The second and third elution peaks from SEC were concentrated using a Vivaspin 
(Sartorius) 6 mL spin concentrator with a 30 kDa cut off. The protein concentration was 
measured using a spectrophotometer at 280 nm, with an additional reading at 260 nm to 
check for DNA contamination. Due to the volumes at which the three peaks of protein 
eluted, it was suggested that the first peak contained aggregates, the second peak contained 
large proteins including dimeric AK:DapDc , and the third peak contained smaller proteins 
including monomeric AK:DapDc.  
3.5   Summary of Cloning Expression and Purification 
In this study, the XFLM_07435 gene, encoding the AK:DapDc enzyme, was successfully 
cloned into the pET30ΔSE expression vector. AK:DapDc was then successfully over-
expressed in Escherichia coli BL21 DE3 cells, after numerous trials. Many more trials 
were carried out to optimise the purification of AK:DapDc by His-Trap and size exclusion 
chromatography. It was found that the addition of sodium chloride and the reducing agent 
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dithiothreitol increased the stability and monodispersity of AK:DapDc. The resulting 
purified protein is not highly pure, but is a significant improvement from anion exchange 
chromatography. 
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4.   Kinetic Assaying of AK:DapDc Using a Coupled 
Assay 
4.1   Introduction 
A major focus of this study is to confirm the predicted functions of Aspartate 
kinase:Diaminopimelate decarboxylase (AK:DapDc). Whether or not both reactions are 
carried out by AK:DapDc will indicate its role in the cell. Xylella fastidiosa has two genes 
encoding aspartate kinase, both of which encode bifunctional enzymes
1
. If both of these 
are functional, this suggests that they have different cellular roles and may be regulated by 
different pathway end-products. X. fastidiosa has only one gene encoding diaminopimelate 
decarboxylase
1
. DapDc is inhibited by lysine in bacteria, so AK:DapDc is likely to also be 
inhibited by lysine 
2
. If both functions catalyse their predicted reactions and both are 
inhibited by lysine, then this confirms the hypothesised regulatory role of AK:DapDc in 
lysine biosynthesis. 
There are three common methods to assay for either aspartate kinase or diaminopimelate 
decarboxylase activity, with the preferred method being coupled enzyme assays in each 
case. There are also colorimetric, spectrophotometric, or radiolabelling endpoint assays. 
The different types of assays measure different aspects of a reaction, so choosing the right 
assay method is important. For this study, measuring the initial rate of reaction is 
important, because kinetic parameters such as maximum velocity (Vmax), Michaelis-
Menten constant (KM), and catalytic efficiency (kcat) can be calculated from the initial 
rate. These parameters contribute to the characterisation of the AK:DapDc enzyme. 
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4.1.1   Aspartate Kinase Assay 
Aspartate kinase catalyses the phosphorylation of aspartate, using ATP to produce aspartyl 
phosphate and ADP (Figure 1.5). Aspartate kinase activity is usually assayed using the 
spectrophotometric aspartyl-hydroxamate endpoint assay
3
, the aspartic semialdehyde 
dehydrogenase coupled enzyme assay
4
, or the pyruvate kinase coupled enzyme assay
4
. The 
aspartyl-hydroxamate assay uses hydroxylamine to measure the formation of a hydroxamic 
acid spectrophotometrically at a wavelength of 540 nm
5
. Hydroxamic acid is formed when 
the hydroxylamine reacts with aspartyl phosphate, the product of the aspartate kinase 
reaction. This is a discontinuous spectrophotometric assay that measures product 
production at different time points after the reaction is stopped with ferric chloride
3
. This 
method does not give an initial rate of reaction, so it is not ideal for measuring the activity 
of AK:DapDc and was not used in this study. 
The aspartic-semialdehyde dehydrogenase (ASADH) coupled assay couples the production 
of aspartyl phosphate by aspartate kinase, with the conversion of aspartyl phosphate to 
aspartate semialdehyde by aspartate semialdehyde dehydrogenase
6
. The formation of 
aspartate semialdehyde occurs with concomitant oxidation of NADPH to NADP
+4
. This 
oxidation can be monitored spectrophotometrically at a wavelength of 340 nm. In contrast 
to the aspartyl-hydroxamate assay, the ASADH assay is continuous. Thus an initial rate of 
reaction can be accurately calculated. 
The pyruvate kinase assay couples two other enzymatic reactions to the aspartate kinase 
reaction (Figure 4.1)
7
. When aspartate is converted to aspartyl phosphate, ATP is used as 
the phosphate source. The ADP produced from the reaction is then used by pyruvate kinase 
to convert phosphoenol pyruvate into pyruvate and ATP. Pyruvate is then converted to 
lactate by lactate dehydrogenase with concomitant oxidation of NADH to NAD
+
. The 
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reduction of NADH is monitored spectrophotometrically at 340 nm. This is another 
spectrophotometric continuous assay which facilitates the accurate measurement of initial 
rates. 
 
Figure 4.1 - Pyruvate kinase assay for aspartase kinase activity. This assay couples the 
AK reaction to pyruvate kinase and lactate dehydrogenase. The disappearance of 
NADH is measured at 340 nm. Drawn in Chemdraw. 
 
For this study, the pyruvate kinase coupled assay was determined to be the most ideal. 
However, due to time constraints and availability of certain substrates, the activity of 
aspartate kinase was not measured.  
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4.1.2   Diaminopimelate Decarboxylase Assay 
DapDc catalyses the decarboxylation of meso-diaminopimelate to give L-lysine and carbon 
dioxide. DapDc activity is commonly assayed by a radiochemical (C
14
) assay, a ninhydrin-
based colorimetric assay, or coupled enzyme assays. The radiochemical assay uses radio-
labelled C
14
 diaminopimelate and measures the evolution of C
14
-containing carbon dioxide 
directly
8
.  
The ninhydrin-based method is a discontinuous colorimetric assay
9
. In this assay, samples 
of the reaction are taken at different time points and the reaction is stopped with glacial 
acetic acid. Ninhydrin reagent is added and incubated at 37°C for 90 minutes. The 
ninhydrin reagent forms coloured products with short chain amino acids containing two 
amino groups
10
. It turns purple with diaminopimelate and yellow with lysine. The 
absorbance of the coloured sample is measured at 440 nm and correlates with 
concentration of lysine present. This method is time consuming and does not give initial 
rate data, so it is not ideal for estimation of AK:DapDc activity. Therefore, this assay was 
not used in this study. 
The coupled enzyme assays link additional reactions to the conversion of meso-
diaminopimelate to lysine and carbon dioxide. In the common two-enzyme assay, the 
carbon dioxide produced from the decarboxylation of meso-diaminopimelate is used by 
PEP carboxylase to convert phosphoenolpyruvate to oxaloacetate. Malate dehydrogenase 
then converts oxaloacetate and NADH to malate and NAD
+
. The disappearance of NADH 
is monitored at 340 nm. 
The coupled assay used in this study couples the DapDc reaction to the reaction of 
saccharopine dehydrogenase (SDH) (Figure 4.2)
11
. The DapDc reaction produces lysine, 
which reacts with α-ketoglutarate, catalysed by saccharopine dehydrogenase, to give 
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saccharopine. This reaction occurs with concomitant oxidation of NADH to NAD
+
. The 
oxidation of NADH is monitored continuously at 340 nm, so this assay also gives an 
accurate calculation of the initial rate of reaction. This assay also requires only one 
coupling enzyme and one set of substrates. 
 
Figure 4.2 - Saccharopine dehydrogenase activity assay reaction 
4.2   Over-expression of Saccharopine Dehydrogenase from 
Saccharomyces cerevisiae 
Escherichia coli BL21 cells were transformed with pET16b-SDH vector (containing the 
gene for SDH from Saccharomyces cerevisiae) according to Section 2.2.7. The 
transformation resulted in many colonies. Several colonies were pre-cultured and SDH was 
expressed according to Sections 2.3.1-2.3.3. A cell sample from 16 hours post-induction 
was analysed via SDS-PAGE and this confirmed that SDH over-expressed (Figure 4.3). 
Optimal conditions for over-expression of SDH included growth of the cells to an OD600 
of 0.7-0.9 at 37°C, induction with 1 mM IPTG and overnight incubation at 26°C. 
4.3   Purification of SDH from E. coli BL21 Cells 
SDH was purified according to Xu et al. (2006) with some modifications according to 
advice from Matthew Perugini’s lab (unpublished data)12. Figure 4.3 shows the SDS-PAGE 
analysis of the purification. The total fraction is a sample of E. coli BL21 cells taken before 
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harvesting, which indicates over-expression of SDH, at 44 kDa. Lysed and centrifuged 
SDH bound well to the column and very little eluted during the washes. Wash 1 is a 
fraction from the collected flowthrough of the first wash. Wash 2 is a fraction of the elution 
due to a low imidazole (20 mM) wash. SDH eluted with 150 mM imidazole
12
, as is shown 
by Elution fractions 2-9 in Figure 4.3. Approximately 15 elution fractions were collected, 
with most of the SDH eluting in the first 10 fractions. There is still a considerable amount 
of SDH bound to the beads, as the Beads fraction was taken after elution of SDH. 
 
Figure 4.3 - SDS-PAGE gel of SDH purification. SDH elution fractions are as 
indicated by the red box. 
4.4   Kinetic Assay 
The SDH assay used in this project is similar to that of Xu et al. (2006) and Ogawa & 
Fujioka (1978), but uses a different buffer system and temperature (200 mM Tris buffer pH 
8.0 at 37°C) following recommendations from Matthew Perugini’s lab (unpublished 
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data)
12, 13
. Xu et al. (2006) used 100 mM HEPES pH 7.0 at 25°C and Ogawa and Fujioka 
used 100 mM potassium phosphate pH 6.8 at 22°C. 
4.4.1    [SDH] vs. Rate of Reaction 
First, the change in initial rate of conversion of lysine and α-ketoglutarate to saccharopine 
with increasing SDH concentration was measured. The purpose of this is to determine the 
concentration of SDH which is proportional to the rate of reaction. No measurements were 
taken above 1.5 μM SDH as the initial rate became too difficult to measure and calculate 
accurately. Figure 3 shows that at concentrations of SDH higher than 1.5 μM, the reaction 
rate appears to level off. 
The SDH concentration proportional to the rate of reaction is 0.25 μM (Figure 4.4). This 
was determined using Figure 4.4. This SDH concentration was used to further determine 
the kinetic parameters of SDH. 
Kinetic Assaying of AK:DapDc Using a Coupled Assay 71 
 
 
 
Figure 4.4 - Graph of the increase in rate of reaction with increase in [SDH]. Each 
data point is an average of three replicates. The error bars represent standard error 
of the mean. Analysed in sedfit. 
4.4.2   [Lysine] vs. Rate of Reaction 
The next set of assays estimated the increase in rate of reaction with increasing lysine 
concentration, while keeping the SDH concentration constant. The purpose of this step was 
to determine KM(Lys) and Vmax of SDH purified in Section 4.3. The concentration of lysine 
ranged from 1-100 mM (1 mM, 2 mM, 5 mM, 10 mM, 15 mM, 25 mM, 50 mM, 100 mM) 
while keeping the α-ketoglutarate (α-KG) concentration at 25 mM. This concentration of 
α-ketoglutarate was used because it is at least ten times the KM(α-KG) reported for ScSDH 
and other SDH enzymes. Xu et al (2006) reports the KM(α-KG) to be 0.11±0.03 mM, while 
Zabriskie & Jackson (2000) report a KM(α-KG) of 0.55 mM
12, 14
. The SDH concentration was 
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0.25 μM, as this was estimated to be in the range of concentrations where the rate of 
reaction is proportional to the concentration of SDH present (See previous section).  
The lysine titration assay (Figure 4.5) shows that the rate of reaction approaches the 
maximum velocity after 50 mM lysine. In the activity assay, lysine is produced by 
AK:DapDc and needs to be immediately converted by SDH to saccharopine, so the affinity 
of SDH for lysine is important to estimate. The affinity for lysine (KM(Lys)) of the SDH 
expressed and purified in this study is 19.3±2.3 mM. The maximum velocity of this 
enzyme is 7.8±0.3 abs/min. 
The SDH purified and used in this study has a lower affinity (KM(Lys)) for lysine than that of 
Xu et al. (2006)
12
. Xu et al. estimated the KM(Lys) to be 1.1 ± 0.2 mM. This difference could 
be due to using different expression and purification conditions. 
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Figure 4.5 - Lysine titration assay. Increase in initial rate of reaction with respect to 
increased lysine concentration, with 0.25μM SDH. Each data point is an average of 
three replicates. Error bars represent the standard error of the mean. Analysed in 
sedfit. 
4.4.3   AK:DapDc Activity 
To test for AK:DapDc, the assay was set up as per Section 1.3.7.3, but without lysine, and 
with a final SDH concentration of 3 μM. The assay mix contained all the substrates 
(excluding lysine), but neither of the enzymes. After incubating each cuvette of assay mix 
(~950 μL) to 37°C, the SDH was added and the absorbance was monitored for 
approximately 10 seconds to ensure there was no SDH activity with the other substrates. 
Then, 20 μL of approximately 1 mg/mL AK:DapDc was added and the absorbance at 
340 nm was monitored for 2 minutes. 
Several different samples of AK:DapDc were assayed: crude/soluble fraction (containing 
all soluble cellular proteins), the AK:DapDc-containing pooled elution peak from His-Trap 
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chromatography, and the pooled concentrated AK:DapDc elution from SEC. Both fresh 
(purified that day) and frozen (with and without glycerol) samples of purified AK:DapDc 
were assayed. Activity was only detected in the crude fraction sample, but as that fraction 
contained all soluble cellular proteins, and presumably also lysine (at a physiological 
concentration) it cannot be confirmed that AK:DapDc was active. 
Thus, AK:DapDc may not be active in 200 mM Tris pH 8.0 at 37°C. X. fastidiosa, the 
bacterium that AK:DapDc originates from, grows optimally at 26-28°C15. This may be the 
optimal temperature for AK:DapDc activity. The melting temperature for AK:DapDc in 
Tris buffer is much higher than 37°C (See DSF results, section 3.4.1.1), so the protein is 
not likely to be denatured due to temperature. 
4.5   Summary of Kinetics 
In this study, the S. cerevisiae SDH was successfully over-expressed and purified (Figure 
4.3). The KM(Lys) and Vmax of SDH were calculated and compared to those found by other 
studies. The difference between the parameters calculated in this study, and those 
calculated by Xu et al. (2006)
12
 may have arisen from differences in the expression system, 
purification conditions, or assay conditions. The next step for this assay is to calculate the 
KM(α-KG) for SDH in order to ensure that the concentration of α-KG included in the assay is 
in fact sufficient to be in excess. If active AK:DapDc is obtained the concentration of SDH 
that is in excess compared to AK:DapDc could be determined. This would prevent SDH 
from being a rate limiting factor in the assay. 
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5.   Biophysical Characterization 
5.1   Introduction 
Protein structure and function are interlinked, therefore structural and biophysical 
characterisation is key to understanding a protein’s cellular role. Biophysical techniques 
provide information on the structural properties of the protein. 
Circular dichroism (CD) evaluates the secondary structures present in the protein and can 
confirm the proportions of α-helical, β-strand/sheet, and unstructured regions1. Web-based 
programs (e.g. PSIPRED) can be used to computationally predict the secondary structures 
present
2
. This computational prediction can show the presence of fold patterns, but also 
show where highly unstructured regions are present. These unstructured regions may affect 
protein solubility and stability, which need to be taken into consideration during expression 
and purification. These techniques can be supported by experimental and theoretical 
techniques that determine or predict tertiary and quaternary structure. 
Generating homology models is a technique used to model the three-dimensional (3D) 
structure of a protein when there is no experimental 3D structure available. The technique 
is based on sequence identity of a target amino acid sequence to a database of amino acid 
sequences of proteins with a known 3D structure. The purpose of homology models is to 
predict the structure as a guide for further applications such as mutagenesis studies and 
protein engineering, as well as supporting experimental x-ray crystallographic structures
3
. 
SWISS-MODEL is a fully automated homology modelling server that has been available 
for 20 years
4
. Recently, it has been improved to be able to model quaternary structure 
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(oligomeric state) in addition to tertiary structure (3D protein folding)
4
. This server was 
selected to construct homology models in this study. 
Analytical Ultracentrifugation (AUC) is an experimental technique which estimates 
physical properties of proteins by measuring the effect of a centrifugal force on the target 
protein
5
. AUC estimates molecular weight, sedimentation coefficient/velocity, oligomeric 
state and shape of proteins
6
. This technique is also used to determine the effects of DNA or 
small molecule binding to the target protein
7
. In this study, AUC was used to determine the 
molecular weight of AK:DapDc and its quaternary structure in solution. 
X-ray crystallography is an integral part of characterising a protein. It provides a 3D 
atomic structure of the protein and can also show oligomeric state. A 3D structure with 
ligands bound can provide an insight into the enzymatic reaction or inhibition of the 
protein. In order to obtain high quality diffracting crystals, screening and optimisation of 
crystallisation conditions must be trialled. During this project four crystal screens were 
trialled at two temperatures, using protein purified using anion exchange chromatography 
and SEC. The preferred method of purification (His-Trap followed by SEC) did not yield 
enough protein for further trials. However, this small scale trial still provides useful 
information about which crystallisation conditions to explore further. 
5.2   Circular Dichroism (CD) 
CD was used to determine the secondary structure and confirm the predicted proportions of 
secondary structures present in AK:DapDc.  
First, buffer tests at 20°C determined which buffer was the best to use (See section 2.4.3). 
The ideal buffer gives a reading of < 600 high tension voltage (HT [V]) for the entire 
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wavelength range measured. An HT voltage of ≥ 600 V indicates the spectrophotometer 
sensor is saturated and measurements taken at that wavelength are not reliable
8
. Salts and 
other buffer additives affect the accuracy of CD measurements at lower wavelengths, by 
increasing the HT voltage to above 600 V at wavelengths less than 200 nm
9
.  
However, AK:DapDc was purified in a buffer containing salt (NaCl), a reducing agent 
(1 mM DTT), and the cofactor (5 μM PLP). Careful optimisation showed that Tris buffer 
(5 mM pH 7.5) was found to be the most ideal concentration. Individually, 1 mM DTT or 
5 μM PLP did not affect the HT voltage significantly, but together they had a noticeable 
effect. Sodium chloride was not added to the CD buffer because it greatly affects the HT 
voltage. Purified protein samples had 200 mM NaCl in the buffer, and a Vivaspin 50 kDa 
cutoff spin concentrator was used to buffer exchange the protein into 5 mM Tris pH 7.5, 
1 mM DTT, 5 μM PLP. 
CD measurements were conducted at two different concentrations His-tagged AK:DapDc: 
0.2 mg/mL and 0.4 mg/mL. These samples of AK:DapDc are not 100% pure. The spectra 
of the two concentrations show a high degree of correlation and indicate that most of the 
secondary structures present are β-elements (Figure 5.1). There is a small peak at 220 nm 
suggesting there are some α-helical elements present also. 
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Figure 5.1 - Circular dichroism spectrum of AK:DapDc at 0.2 mg/mL and 0.4 mg/mL. 
 
Online CD analysis tools CDNN, K2D, and ContinLL (via Dichroweb, 
http://dichroweb.cryst.bbk.ac.uk/) were used to determine the proportions of secondary 
structures from the CD spectra of two different concentrations of AK:DapDc (Table 5.1)
10-
13
. The proportions of secondary structures predicted by PSIPRED and homology 
modelling (See section 5.3) are different to the observed proportions. This could be due to 
the protein being partially unfolded, the sample not being very pure, or the prediction being 
incorrect. The CD profile of an unfolded protein has predominantly β-elements and few α-
helices
1
. DSF tests showed that with all samples there was some degree of fluorescence 
present before the thermal shift assay. It is likely that AK:DapDc is partially denatured and 
unfolding at 20°C. 
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Table 5.1 - Proportions of secondary structures present in AK:DapDc. 
Secondary 
elements 
PSIPRED 
prediction 
CDNN 
0.2 mg/mL 
CDNN 
0.4 mg/mL 
K2D ContinLL 
0.4 mg/mL 
α-helix 36.1% 16 % 16 % 9 % 11 % 
β-strands 21.5% 50 % 50 % 43 % 57 % 
Random coil 42.4% 34 % 34 % 48 % 32 % 
 
5.3   Homology Models 
To predict a possible three-dimensional structure for AK:DapDc, homology models were 
created with SWISS-MODEL (http://swissmodel.expasy.org/)
4, 14, 15
. The AK:DapDc 
translated amino acid sequence was entered into SWISS-MODEL. The bifunctional 
AK:DapDc has the highest sequence similarity with two proteins: the DapDc domain has 
highest similarity with the DapDc from E. coli (EcDapDc - 1KNW) while the AK domain 
has highest similarity with the AK from Arabidopsis thaliana (AtAK – 2CDQ). 
5.3.1   DapDc – 1KNW 
The C-terminal domain of AK:DapDc (residues 510-867) has the highest similarity with 
the E. coli DapDc (1KNW). 1KNW is 425 residues long and contains 30% α-helix, 22% β-
sheet, and 48% random coil. This model template had ~30% identity with AK:DapDc 
(Figure 5.2). 
All DapDc enzymes are TIM-barrel enzymes with an additional C-terminal β-sandwich 
domain and belong to the fold type III class of PLP-dependent enzymes
16
. This type of 
PLP-dependent enzyme is catalytically active as a dimer, as both monomers contribute 
residues to the active site
17
. DapDc is a homodimer and the active sites are formed by the 
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interface of both subunits
18
. This suggests that AK:DapDc is also an obligate dimer in 
order to be catalytically active.  
DapDc requires pyridoxal 5-phosphate (PLP) as a cofactor to carry out its reaction. 
SWISS-MODEL modelled PLP into the DapDc homology model, as all of the residues that 
interact with PLP in the template (1KNW) are present in AK:DapDc (Figure 5.2). PLP is 
located in the active site of DapDc at the C-terminal face of the TIM barrel region. 
 
Figure 5.2. Homology model of XfDapDc based on the structure of EcDapDc (PDB 
ID: 1KNW) 
5.3.2   AK – 2CDQ 
Homology modelling of the AK domain of the AK:DapDc amino acid sequence (residues 
12-480) using SWISS-MODEL predicts the domain to have a structure similar to that of 
the AK from Arabidopsis thaliana (PDB ID: 2CDQ)
19
. The sequence identity was ~30%. 
This is also very similar to the structure of E.coli’s AK III, which forms dimers and 
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tetramers in solution (also ~30% identity). This structure does not have any substrates or 
cofactors modelled in (Figure 5.3). 
AK has two domains: an N-terminal catalytic domain, and a C-terminal regulatory domain 
(Figure 5.3). The catalytic domain has two lobes: the N-lobe and the C-lobe. The active 
site of the enzyme lies between the two lobes of the catalytic domain. The regulatory 
domain also has two parts: two ACT (aspartate kinase:chorismate mutase:TyrA) regulatory 
domain repeats. ACT regulatory domains have a conserved βαββαβ topology and are often 
found in pairs, i.e. tandem repeats
20. 
 
Figure 5.3. Homology model of AK from Arabidopsis thaliana (PDB ID: 2CDQ) 
 
AK enzymes can dimerise in two different ways: either the regulatory domains of each 
monomer associate or the two catalytic domains interact
21
. The E.coli AK dimerises by 
association of the regulatory ACT domains
22
. It also forms a tetramer, by association of the 
catalytic domains of each dimer
22
. This suggests that the interface region required for 
tetramerisation in EcAK may be present in AK:DapDc and facilitate dimerisation. 
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5.4   Analytical Ultracentrifugation (AUC) 
The purpose of AUC in this study was to determine the molecular weight and oligomeric 
state of AK:DapDc in solution. The first sample of AK:DapDc analysed by AUC was His-
tagged, but purified by anion exchange chromatography and size exclusion and eluted as 
one peak (See section 3.4). 
Three concentrations of AK:DapDc were used to investigate the concentration dependence 
of any higher oligomeric states: 0.1 mg/mL, 0.4 mg/mL, 0.8 mg/mL. Wavelength and 
radial scans determined 290 nm and 5.8-7.3 cm radial length to be good parameters for the 
experiment. The samples were spun at 40,000 rpm and 250 scans were taken. The Fit data 
and residuals plots for each concentration are shown in Figure 5.5 and Figure 5.6. 
 
Figure 5.4. Sedimentation distribution of AK:DapDc purified by anion exchange and 
size exclusion, analysed in sedfit. Normalized to (0 1.0) 
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The sedimentation coefficient distribution plots for the three concentrations are overlaid in 
Figure 5.4 to investigate whether there is a concentration-dependent dimerization of 
AK:DapDc. The sample of the lowest concentration (0.1 mg/mL) has a peak at ~4.2 [S] 
corresponding to ~88.5 kDa monomeric AK:DapDc and a peak at ~6.8 [S] corresponding 
to ~180 kDa dimeric AK:DapDc. These proteins are 15.6% and 19.4% of the total protein 
present, respectively. The sample of 0.4 mg/mL AK:DapDc has a peak at ~9 [S] 
corresponding to ~164 kDa dimeric AK:DapDc. This protein makes up 56.9% of the total 
protein present. The sample with the highest concentration (0.8 mg/mL) has a peak at ~6.8 
[S] corresponding to ~96.8 kDa monomeric AK:DapDc, and a peak at ~10 [S] 
corresponding to ~179 kDa dimeric AK:DapDc. These two peaks are 13.7% and 37.5% of 
the total protein. Comparing the lowest and highest concentration data, there is a much 
higher proportion of dimer in the 0.8 mg/mL sample and a more equal proportion of 
monomer and dimer at the lowest concentration. This suggests that the higher the 
concentration of AK:DapDc, the greater the proportion of dimer present. However, even at 
low concentrations there is still a detectable amount of dimer present. 
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Figure 5.5. AUC fit data for AK:DapDc sample purified by anion exchange and size 
exclusion, analysed in sedfit. 
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C. 
 
Figure 5.6. AUC residuals data for AK:DapDc purified by anion exchange and size 
exclusion, analysed in sedfit. 
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The second set of AK:DapDc samples analysed by AUC was His-tagged and purified by 
His-Trap chromatography and size exclusion chromatography (SEC). AK:DapDc eluted 
from SEC as three peaks. The first peak eluted within the void volume of the column and 
was determined by DSF to be aggregated. Peaks two and three had a small amount of 
aggregation, but were folded and DSF gave a melting profile for both peaks. Three 
concentrations of peak two were analysed by AUC: 0.1 mg/mL, 0.4 mg/mL, and 
0.8 mg/mL. Two concentrations of peak three were analysed: 0.1 mg/mL and 0.8 mg/mL. 
Peak two from SEC was analysed at 288 nm and at 40,000 rpm. 150 scans were taken. Fit 
data and residuals plots for each concentration are shown in Figure 5.7 and Figure 5.8.  
The sample with the lowest concentration (0.1 mg/mL) resulted in a sedimentation 
distribution with a peak at ~7.4 [S] corresponding to ~97.8 kDa monomeric AK:DapDc 
(Figure 5.9). This protein constitutes 24.4% of the total protein in the sample. The sample 
of 0.4 mg/mL AK:DapDc had a peak at ~8.99 [S] potentially corresponding to ~160 kDa 
dimeric AK:DapDc. This protein is 17.5% of the protein in the sample. The most 
concentrated AK:DapDc sample (0.8 mg/mL) had a distribution profile with a peak at ~6.5 
[S] which corresponds to ~99.4 kDa monomeric AK:DapDc and a peak at ~10.3 [S] which 
indicates the presence of ~198 kDa dimeric AK:DapDc. These proteins constitute 17.2% 
and 11.8% of the total protein sample, respectively. There are predominantly proteins 
corresponding to the predicted size of an AK:DapDc dimer (~195 kDa). This suggests that 
this peak largely contains dimeric AK:DapDc. 
Biophysical Characterization 89 
 
 
A. 
 
B. 
 
C. 
 
Figure 5.7. AUC fit data plots for peak two of AK:DapDc purified by His-Trap and 
size exclusion, analysed in sedfit. 
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Figure 5.8. AUC residuals plots for peak two of AK:DapDc purified by His-Trap and 
size exclusion, analysed by sedfit. 
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Figure 5.9. Sedimentation distribution for AK:DapDc from peak two of size exclusion, 
analysed in sedfit. Normalized to (0-1.0) 
 
Peak three from AUC was analysed at 285 nm, 45,000 rpm and at two concentrations 
(0.1 mg/mL and 0.8 mg/mL). The fit data and residuals plots for each concentration are 
shown in Figure 5.10 and Figure 5.11. This peak from SEC is hypothesised to be 
monomeric AK:DapDc. The lower concentration (0.1 mg/mL) produced a sedimentation 
distribution with a peak at ~6.2 [S] corresponding ~102 kDa monomeric AK:DapDc 
(Figure 5.12). This peak constitutes 74.2% of the protein in the sample. There was no peak 
corresponding to dimeric AK:DapDc (~195 kDa). The sedimentation distribution for the 
higher concentration of AK:DapDc (0.8 mg/mL) has a peak at ~6.2 [S] corresponding to 
monomeric AK:DapDc. This protein is 68.5% of the protein in the sample. This 
concentration shows the presence of larger proteins more than the 0.1 mg/mL sample, but 
there is no peak corresponding to dimeric AK:DapDc. This suggests that the size exclusion 
peak three is indeed monomeric AK:DapDc, and that this state is not concentration 
dependent in the range measured. 
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Figure 5.10. AUC fit data for peak three of AK:DapDc purified by His-Trap and size 
exclusion, and analysed by sedfit. 
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Figure 5.11. AUC residuals plots for peak three of AK:DapDc purified by His-Trap 
and size exclusion, analysed by sedfit. 
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Figure 5.12. Sedimentation distribution for AK:DapDc from peak three of size 
exclusion, analysed by sedfit. Normalized to (0-1.0) 
5.5   Crystal Screens 
Four crystal screens were trialled at two temperatures (5°C and 20°C). The protein used in 
this trial was concentrated using a Vivaspin spin concentrator (Sartorius). The four crystals 
screens are: Clear Strategy Screen™ I HT-96, JCSG-plus™ HT-96, Morpheus™, and 
PACT premier™ HT-96 (moleculardimensions.com). 
Clear Strategy Screen™ I HT-96 screens from pH 5.5 – 8.5, combining different PEGs 
(precipitants) and salts, to give an easily optimised, high-throughput screen. JCSG-plus™ 
HT-96 is a sparse-matrix screen based on previously successful conditions. It screens from 
pH 4.0-10.0, using neutralized organic acids and polyalcohol conditions. Morpheus™ 
covers a range of pH (6.5-8.5), PEGs, and salts, but also includes low molecular weight 
ligands found to occur in many crystal structures. PACT premier™ HT-96 is a pH (4.0-
9.0), anion, cation, trial, which tests each of these factors against the precipitant PEG 3350. 
Biophysical Characterization 95 
 
 
No crystals were found in any of the trials. Each screen trialled at both 5°C and 20°C to 
test whether the protein was more stable at a low temperature and if this would slow down 
the process of concentration to give crystals rather than precipitate. In both temperatures, 
only precipitate or amorphous structures were found (Figure 5.13). DSF showed that 
AK:DapDc was denatured at pH 4-6, and was folded at pH 6 but not particularly stable. 
Buffers that caused precipitation and denaturation during buffer exchange and DSF (e.g. 
HEPES), resulted in precipitation instead of crystallisation. Magnesium chloride does not 
stabilise AK:DapDc, thus crystallisation conditions containing magnesium chloride also 
resulted in precipitate. 
A. B. 
  
Figure 5.13. Examples of precipitate (A.) and amorphous structures (B.) found in all 
crystal screens. 
 
Morpheus™ uses amino acids such as racemic lysine to screen ligands that are likely to co-
crystallize with a protein. Lysine is the predicted inhibitor for both domains of AK:DapDc, 
and so binding of lysine to either or both domains may stabilise AK:DapDc and aid in 
crystallisation. It is unclear whether it will aid in crystallisation as the combination of 
conditions resulted in precipitation, despite the presence of lysine. 
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Ammonium sulphate precipitates AK:DapDc (See Section 3.4.1), thus the conditions in 
JCSG-plus HT-96, Morpheus™, and PACT premier HT-96 containing above 0.1M 
ammonium sulphate have resulted in precipitation of AK:DapDc. 
5.6   Summary of Results 
CD analysis of AK:DapDc at two concentrations estimated significantly different 
proportions of 2° structures present compared to computational prediction and homology 
modelling. The proportion of α-helical elements present is much lower, indicating that 
AK:DapDc is unstable and unfolding at 20°C, or the predicted structure of AK:DapDc is 
very different from the actual structure in solution. It is more likely that AK:DapDc is 
unfolded and partially denatured, as it is an unstable protein (See Chapter three). 
Homology modelling created two models for AK:DapDc from the monofunctional forms 
of aspartate kinase and diaminopimelate decarboxylase from Arabidopsis thaliana and 
Escherichia coli, respectively. These two template enzymes are well documented and so 
information about the domain structure and oligomeric state of AK:DapDc can be inferred. 
This model will need to be confirmed by x-ray crystallography. There is a linker 
connecting the two functions of AK:DapDc which has not been modelled. This linker is 
approximately 30 residues long and its flexibility may be affecting the 3° and 4° structure 
of AK:DapDc. This could explain the difference between the CD results and the predicted 
secondary structure. 
The 3° and 4° structure of purified AK:DapDc was investigated using AUC. AK:DapDc 
samples purified using anion exchange and SEC contain both monomers and dimers of 
AK:DapDc, with the higher concentration containing a much greater proportion of dimer. 
This may be due to the prediction that AK:DapDc is an obligate dimer for DapDc to be 
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active. AK:DapDc purified by IMAC and SEC eluted from SEC in three peaks. Peaks two 
and three were hypothesised to contain AK:DapDc dimer and monomer, respectively. AUC 
results suggest that this may be the case. 
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6.   Discussion 
6.1   Introduction 
Xylella fastidiosa is greatly researched worldwide due to its significant impact on many 
economically important crops. X. fastidiosa has not yet been detected in New Zealand, but 
overseas evidence has shown that it affects commercial crops known to be important to the 
New Zealand economy
1, 2
. The New Zealand wine industry is worth $1.5 billion dollars 
annually, and exports $1.2 billion dollars of wine annually
3
. The ornamental plant and 
floriculture industry is worth approximately $70 million annually
4
. Biosecurity New 
Zealand considers X. fastidiosa to be enough of a risk that it has developed an assay for the 
detection of X. fastidiosa 
5
.  
Research into its biology and mechanism of pathogenesis are essential for combating X. 
fastidiosa infection, more so because the bacteria can remain dormant in grapes throughout 
much of the year and can spread to over 100 species of plants where it can also remain 
dormant and asymptomatic
6
. X. fastidiosa’s metabolism and biosynthetic pathways are 
equally as important to study as many of these are essential pathways.  
Aspartate kinase:Diaminopimelate decarboxylase (AK:DapDc) is the focus of this study 
because it is part of an essential pathway for X. fastidiosa, and is an intriguing and 
extremely rare bifunctional enzyme. Due to its uniqueness, this enzyme potentially offers 
an antibiotic target to control X. fastidiosa infections
7
. 
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6.2   Expression of AK:DapDc 
Over-expression of Aspartate kinase:Diaminopimelate decarboxylase was achieved in this 
study, after many expression trials. Although over-expression of AK:DapDc can be 
achieved in Escherichia coli BL21 cells, upon cell lysis and purification most of the 
AK:DapDc protein is insoluble and aggregated. Buffer screens and trials have improved 
AK:DapDc solubility and stability enough to perform a number of biophysical techniques 
on the protein. Other techniques that would further characterise the protein and support the 
data and hypotheses in this study require more pure, stable purified protein. If the stability 
issues arise from mis-folding, which facilitates aggregation, then the most effective 
solution may be to modify the expression system and conditions.  
E. coli has many advantages as an expression system, but not every gene can be expressed 
well in this organism 
8
. A significant fraction of some recombinant proteins fails to fold 
correctly and aggregates into inclusion bodies 
9
. This can be due to properties of the gene 
sequence such as differences in codon usage between the recombinant gene and E. coli 
cells
10
, the protein’s ability to fold correctly, the stress of over-expression on the cells, or 
suboptimal intracellular conditions (e.g. pH or redox conditions) 
11
. Codon usage was 
investigated using Graphical Codon Usage Analyser (www.gcua.de) which compares 
codon usage in a query gene sequence to the codon usage of another species, e.g. E. coli. 
There were some differences in codon usage, but the gene overexpressed well in E. coli so 
optimisation was not carried out. 
This study has trialled alternative expressions systems and conditions such as expression in 
E. coli BL21 DE3 Rosetta cells which contain rare tRNA genes, expression with a GST-tag 
to aid solubility and folding, media supplementation with 1% glucose, short expression 
time with high level IPTG induction, slow expression at 4°C with low IPTG induction.  
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AK:DapDc expression was trialled in E. coli Rosetta cells, but this didn’t appear to 
significantly improve the solubility of the recombinant protein. Codon usage in the 
AK:DapDc gene (XFLM_07435) was compared to that used by E. coli, and there were a 
few noticeable differences. The effect of expression with extra tRNA genes may not be 
enough to help correct the mis-folding of AK:DapDc. 
Cloning the AK:DapDc gene (XFLM_07435) into a vector (pET30-GST) so that there is 
an N-terminal GST tag has been attempted in this study. The GST tag is both a solubility 
and affinity tag, and aids in the stability of proteins it is fused to. Despite sequencing 
confirming that the gene was inserted in the vector, a GST-AK:DapDc fusion protein did 
not express.  
The addition of 1% glucose to pre-cultures and large cultures was also trialled in this study. 
The addition of glucose prevents leaky expression
12
 and is also reported to increase the 
solubility of recombinant proteins. The glucose did not significantly improve the solubility 
of AK:DapDc. Likewise, varying the length of time given for expression and the 
concentration of IPTG did not have a noticeable effect on solubility. 
Other promising methods that have not been trialled include auto-inducing medium, co-
expression with chaperone proteins that aid in proper folding and separate expression of 
the AK:DapDc domains. 
Auto-inducing medium is one method used to improve the solubility of recombinant 
proteins
13
. The medium contains lactose, which E. coli breaks down into galactose and 
glucose. The glucose is used as an energy source and also inhibits induction. The galactose 
induces expression of recombinant genes inserted into vectors which contain a T7 lac 
promoter. The slow break down of lactose restricts the amount of galactose that is available 
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to induce expression and thus expression occurs slowly. Slower expression can aid in better 
folding of some recombinant proteins. Media additives have improved the solubility of 
small proteins (25-45 kDa). 
While small proteins are often helped by the conditions already mentioned large 
recombinant proteins may require more assistance. Chaperone co-expression or expression 
as two separate domains may have the greatest effect on AK:DapDc solubility. 
E. coli has endogenous chaperones which assist in folding at least 300 E. coli proteins 
14
. It 
appears that during over-expression of recombinant protein the cells’ chaperones become 
overwhelmed and so much of the protein becomes mis-folded and aggregates into 
inclusion bodies 
11
. 
Alternatively, if the overall structure is too unstable, the two halves of AK:DapDc could be 
expressed separately. Secondary structure prediction can be used to predict the boundaries 
of secondary structures, and create two conctructs without affecting local secondary 
structures. A protocol which investigates different combinations of N- and C-terminal 
positions could be used to identify what length of tail gives the protein the most stability 
15
. 
Separate expression would also simplify enzyme kinetics. When investigating inhibition, 
expressing the protein as separate domains allows you to tell which domain the inhibitor is 
binding to, to inhibit activity. It can be established whether or not both domains are 
inhibited by lysine, and also threonine and methionine. Conversely, it would be intriguing 
to determine whether binding of an allosteric inhibitor to one domain affects the activity of 
the other domain. 
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6.3   Purification of AK:DapDc 
Many purification trials were also carried out to try to troubleshoot and optimise the 
process. AK:DapDc purification was first trialled using Co
2+
 HisTrap chromatography, but 
the protein would not elute from the column. This problem lead to the hypothesis that 
AK:DapDc may have been interacting with the Co
2+
 in HisPur column
16
. Aspartate kinase 
has been shown to interact with cobalt, which becomes oxidised to inert Co
3+
. This 
prevents the enzyme from being catalytically active. The reducing agent dithiothreitol 
(DTT) was recommended for the removal of Co from the metal binding site of aspartate 
kinase
16
. Adding DTT to the purification buffers allowed the AK:DapDc protein to elute 
from the Co
2+
 HisTrap column. This was the preferred method of purification in this study 
as it was much more selective than anion exchange.  
The binding of Co
2+
 to the metal binding site of aspartate kinase could be tested by 
isothermal titration calorimetry (ITC) which measures the heat of interactions of molecules 
and proteins in solution. This property of cobalt could also be investigated via a SYPRO 
Orange binding assay which allows detection of nucleotide and divalent cation binding to 
kinases. The effect of adding Co
2+
 to protein samples could also be analysed by differential 
scanning fluorimetry (DSF) which would indicate an increase or decrease in AK:DapDc 
stability with Co
2+
 binding or analytical ultracentrifugation (AUC) which could show a 
change in overall shape and oligomeric state with Co
2+
 binding. 
The benefit of including a reducing agent such as DTT in the purification buffers is that the 
formation of soluble aggregates may be prevented. There may be unforeseen negative 
effects of adding a reducing agent. Creating a reducing environment may affect 
dimerisation and activity.  
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A major issue in this study was that solubility is not the best marker for quality in purified 
protein. Mono-dispersity is a more appropriate measure of quality. Soluble aggregates of 
folded and mis-folded protein have been observed
9
, and these may cause further 
aggregation and instability of properly folded AK:DapDc. They also contaminate purified 
samples of protein, and may prevent the use of certain techniques on the sample. The use 
of an aggregation index/rate as a measure of quality would be more effective than merely 
measuring concentration of soluble protein present. DTT and NaCl were added to the 
purification buffers in this study, and this was sufficient to prevent further aggregation and 
allow characterisation techniques to be carried out. 
The DSF buffer screen protocol used in this study was very helpful for purification 
optimisation
17
. The buffer screen was able to identify which buffers, pH range and salt 
concentration gave the most stable protein (See Section 3.4.1.1). However, this is 
effectively a buffer exchange on already purified protein. Whether the buffers that result in 
the highest melting temperatures are able to solubilise AK:DapDc during cell resuspension 
and lysis is unsure. Cation exchange chromatography was trialled in this study using two 
buffers identified by DSF as stabilising AK:DapDc, but was unsuccessful (See Section 
3.4.1.1). This may have been due to the buffers’ inability to solubilise AK:DapDc during 
resuspension and cell lysis. DSF is also useful for detecting aggregation in protein samples, 
without running a thermal assay. Taking a photo of fluorescence present with the iQ5 RT-
PCR machine was used to confirm that SEC peak one consisted of aggregated AK:DapDc 
(Section 3.4.3). This showed that peaks two and three, hypothesised to be dimeric 
AK:DapDc and monomeric AK:DapDc respectively, had a small degree of 
aggregation/fluorescence. 
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6.4   Kinetic assay 
The parameters calculated in this study for ScSDH are slightly different from those 
reported in previous studies. In this study SDH was resuspended in 200 mM Tris buffer 
pH 8.0 and the assay was carried out at 37°C, while Xu et al. (2006) used 100 mM HEPES 
pH 7.0 and the assay was carried out at 25°C18. 
The saccharopine dehydrogenase assay is an effective assay for detecting and measuring 
the activity of enzymes such as diaminopimelate decarboxylase. It requires only one 
coupling enzyme and so only one set of kinetic parameters need to be calculated to set up 
the assay. This is an ideal assay to test for activity in AK:DapDc. However, it cannot be 
used to test for inhibition of AK:DapDc as the predicted inhibitor, L-lysine
19, 20
, is a 
substrate for ScSDH. In the assay, ScSDH is present in excess, thus any L-lysine 
present/added is rapidly converted by ScSDH to saccharopine. Thus the activity observed 
will be ScSDH activity, and not AK:DapDc activity. ScSDH is reported to have absolute 
specificity for lysine
21
 so an L-lysine analogue inhibitor that ScSDH can’t convert to 
saccharopine could be used to investigate inhibition of AK:DapDc. A coupled assay in 
which the coupling enzyme(s) does not use the inhibitor as a substrate could also be used 
to test for inhibition, e.g. the PEP carboxylase/malate dehydrogenase coupled assay
22
. 
6.5   Biophysical characterisation 
Circular dichroism (CD), homology modelling and AUC were used to biophysically 
characterise AK:DapDc. DSF analysis of AK:DapDc also added to the characterisation of 
the protein. These techniques were used to elucidate information about the secondary, 
tertiary and quaternary structure of AK:DapDc. CD suggests that AK:DapDc contains both 
α-helices and β-strands, but the proportions are significantly different from the predicted 
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secondary structure proportions. AUC and homology modelling indicate that AK:DapDc 
exists as both monomer and dimer, but may be functional as a dimer. Homology modelling 
provides clues as to how AK:DapDc might form dimers. 
CD gave an average secondary structure profile of AK:DapDc of 13% α-helices, 50% β-
strands, and 37% random coil using the programs CDNN
23
, K2D
24
, and ContinLL
25
. This 
is significantly different from the proportions predicted computationally: 36% α-helices, 
21.5% β-strands, and 42.5% random coil. This could be due to contamination by other 
proteins present or unfolding of AK:DapDc at 20°C. The purification of AK:DapDc 
resulted in a protein sample with some small contaminant proteins, which may be altering 
the secondary structure profile obtained. The CD profile may also be affected by the 
unfolding of some of the AK:DapDc present. When proteins unfold their secondary 
structure profile can change dramatically, with a decrease in ellipticity and a decrease in 
the proportion of α-helices present26. Some proteins that are only partially unfolded still 
have detectable α-helices in the spectra26. However, the folded and unfolded profiles of a 
protein are quite different for different domain structures
27
. As mentioned above, soluble 
aggregates can be present in a protein sample and can consist of partially unfolded protein 
as well as folded protein
9
.  This may represent the state of AK:DapDc, as there is a degree 
of aggregation present in purified samples. This would result in a profile like that of Figure 
1. Section 5.2, where some of the α-helices have unfolded giving a less distinct negative 
band at 222 nm and 208 nm, but the β-strands are still present, with a prominent negative 
band at 218 nm
27
. 
Homology modelling using SWISS-MODEL predicted AK:DapDc to have highest 
homology with the aspartate kinase from Arabidopsis thaliana (PDB ID: 2CDQ)
28
 and the 
diaminopimelate decarboxylase from E. coli (PDB ID: 1KNW)
29
. There is also a 30 amino 
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acid sequence between the predicted conserved domains of the two models of AK:DapDc 
that is potentially unstructured random coil. Both aspartate kinase and diaminopimelate 
decarboxylase are known to form dimers and tetramers
19, 30
. Aspartate kinase can dimerise 
either by the ACT regulatory domains interacting, or by the catalytic domains interacting. 
The A. thaliana aspartate kinase dimerises by overlapping the ACT regulatory domains 
(Figure 1. A). Diaminopimelate decarboxylase dimerises by the TIM-barrel of one 
monomer interacting with the β-sandwich domain of the other monomer30, as with Figure 
1.C below. There is not tetrameric crystal structure of the diaminopimelate decarboxylase 
from E. coli, but the tetrameric structure for Mycobacterium tuberculosis (28% sequence 
identity with 1KNW) shows that the sides of the TIM-barrels, and part of the β-sandwich 
domain of each monomer interacts with the corresponding regions of a monomer from the 
other dimer (Figure 1.D). The dimer interface is between two anti-parallel β-strands from 
the β-sandwich domains30. 
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A. B. 
  
C. D. 
 
 
Figure 6.1. Crystal structures showing the dimerisation and tetramerisation of AK 
and DapDc. A: the dimerisation via the regulatory domains of aspartate kinase from 
A. thaliana, showing the dimer rotated 90°, B: the tetramerisation of aspartate kinase 
from E. coli. The black box shows the region where the two dimers interact, C: The 
dimerisation of diaminopimelate decarboxylase from E. coli, D: the tetramerisation of 
diaminopimelate decarboxylase from M. tuberculosis.   
 
It is unclear how the domains of AK:DapDc would interact and sit in three dimensional 
space as a monomer or a dimer. The monomer may adopt some of the features of the 
dimers of both of the template structures predicted by SWISS-MODEL (Figure 2). The 
ACT domains of the aspartate kinase could overlap the β-sandwich domain of the 
diaminopimelate decarboxylase function. 
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A. 
 
B. 
 
Figure 6.2 Hypothesised AK:DapDc monomeric and dimeric structure based on the 
dimerisation and tetramerisation of the homology models 1KNW and 2CDQ.  A: the 
hypothesised monomeric structure of AK:DapDc with the ACT 1 and 2 domains 
overlapping the β-sandwich domain from DapDc. The C-terminal of AK joins up to 
the N-terminal of DapDc via a linker of unknown conformation.  B: The hypothesised 
dimeric structure of AK:DapDc 
 
The AUC data analysed in this study suggests the presence of both monomer and dimer in 
solution, but this cannot be confirmed because all samples contained a number of 
contaminating species and also a small degree of aggregation. 
Crystal trays did not result in any crystals. Due to the instability and aggregation present in 
purified AK:DapDc the protein was beginning to aggregate and precipitate at 10 mg/mL, 
before being added to the crystallisation solutions. This resulted in most conditions 
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precipitating the protein (Figure 11, section 5.5). Hopefully if more stable protein could be 
produced then these same crystal trials would provide more information about crystallising 
AK:DapDc. The AK:DapDc purified in this project began precipitating at higher 
concentrations (~10 M), the concentration of protein used in crystallisation trials could be 
decreased to 5 M to prevent unwanted aggregation. 
6.6   Concluding Remarks 
In summary, the AK:DapDc protein from X. fastidiosa was successfully overexpressed and 
purified in this study. Its properties were investigated using several biophysical techniques, 
but these were affected by sample purity and aggregation. The AK:DapDc samples purified 
in this study could not catalyse the diaminopimelate decarboxylase reaction. However, the 
expression, purification and buffer optimisation work done in this project provides a good 
base of knowledge about studying AK:DapDc. 
The next steps for this project, in my view, would be to try co-expressing AK:DapDc with 
chaperones or expressing the two domains separately. The protein could then be purified 
more easily. I would like to see this protein crystallised and its structure elucidated by x-
ray crystallography as I think this protein could help increase our understanding of 
bifunctional proteins. AK:DapDc is a very interesting protein and further research could 
aid in the control of X. fastidiosa. 
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Appendix I: Modified Buffers for DSF Buffer Screening 
Table 6.1 - Modified buffers developed in this study for use in DSF buffer screening, 
adapted from the protocol described in Seabrook & Newman (2013)
1
. 
Position Contents pH [NaCl] 
A1, A2, A3 Lysozyme (+ve control) 8 50mM 
A4, A5, A6 Water control n/a 200mM 
A7, A8, A9 Water control n/a 500mM 
A10, A11, A12 Protein control  n/a 
B1, B2, B3 Sodium acetate 4.0 200mM 
B4, B5, B6 Sodium acetate 4.0 500mM 
B7, B8, B9 Sodium acetate 5.0 200mM 
B10, B11, B12 Sodium acetate 5.0 500mM 
C1, C2, C3 MES 6.0 200mM 
C4, C5, C6 MES 6.0 500mM 
C7, C8, C9 Citrate 4.0 200mM 
C10, C11, C12 Citrate 4.0 500mM 
D1, D2, D3 Citrate 5.0 200mM 
D4, D5, D6 Citrate 5.0 500mM 
D7, D8, D9 Citrate 6.0 200mM 
D10, D11, D12 Citrate 6.0 500mM 
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Position Contents pH [NaCl] 
E1, E2, E3 Sodium phosphate 6.0 200mM 
E4, E5, E6 Sodium phosphate 6.0 500mM 
E7, E8, E9 Sodium phosphate 7.0 200mM 
E10, E11, E12 Sodium phosphate 7.0 500mM 
F1, F2, F3 Bis-Tris Propane 7.0 200mM 
F4, F5, F6 Bis-Tris Propane 7.0 500mM 
F7, F8, F9 Bis-Tris Propane 8.0 200mM 
F10, F11, F12 Bis-Tris Propane 8.0 500mM 
G1, G2, G3 Bis-Tris Propane 9.0 200mM 
G4, G5, G6 Bis-Tris Propane 9.0 500mM 
G7, G8, G9 Tris 7.0 200mM 
G10, G11, G12 Tris 7.0 500mM 
H1, H2, H3 Tris 8.0 200mM 
H4, H5, H6 Tris 8.0 500mM 
H7, H8, H9 Sample Benchmark n/a n/a 
H10, H11, H12 Dye control n/a n/a 
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Appendix II: Plasmid Maps 
pCR2.1-TOPO, pBluescript-SK
+
, pET30ΔSE plasmid maps follow. pET30GST is a 
modified version of pET30ΔSE with the N-terminal His-tag replaced by a GST tag. 
Comments for pCR®2.1-TOPO®
3931 nucleotides
LacZα fragment: bases 1-547
M13 reverse priming site: bases 205-221
Multiple cloning site: bases 234-357
T7 promoter/priming site: bases 364-383
M13 Forward (-20) priming site: bases 391-406
f1 origin: bases 548-985
Kanamycin resistance ORF: bases 1319-2113
Ampicillin resistance ORF: bases 2131-2991
pUC origin: bases 3136-3809
CAG GAA ACA GCT ATG ACC ATG ATT ACG CCA AGC TTG GTA CCG AGC TCG GAT CCA CTA
GTC CTT TGT CGA TAC TGG TAC TAA TGC GGT TCG AAC CAT GGC TCG AGC CTA GGT GAT
T7 Promoter M13 Forward (-20) Primer
Not I Xho I Nsi I Xba I Apa I
lacZα
f1
ori
+1
Plac
Ampicillin
pU
C
o
ri
Ka
na
m
yc
in
pCR®2.1-TOPO®
3.9 kb
M13 Reverse Primer
lacZα ATG Kpn I Sac I Spe IBamH IHind III
EcoR IEcoR IBstX I
BstX IEcoR V
AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG CCC TAT
TCT ATA GGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AGC GGG ATA
AGT GAG TCG TAT TAC AAT TCA CTG GCC GTC GTT TTA CAA CGT CGT GAC TGG GAA AAC
TCA CTC AGC ATA ATG TTA AGT GAC CGG CAG CAA AAT GTT GCA GCA CTG ACC CTT TTG
PCR ProductGTA ACG GCC GCC AGT GTG CTG GAA TTC GCC CTT           AAG GGC GAA TTC TGCCAT TGC CGG CGG TCA CAC GAC CTT AAG CGG GAA           TTC CCG CTT AAG ACG
f1 (+) ori
lacZ'
MCS
Kpn I
Sac I
P lac
pUC ori
ampicillin
pBluescript SK+
3.0 kb
f1 (+) origin 138–444
β-galactosidase α-fragment 463–816
multiple cloning site 653–760
lac promoter 817–938
pUC origin 1158–1825
ampicillin resistance (bla) ORF 1976–2833
pBluescript SK (+/–) Multiple Cloning Site Region
(sequence shown 601–826)
M13 Reverse primer binding site
β α-gal -fragment
...GCTTTTGTTCCCTTTAGTGAGGGTTAATTTCGAGCTTGGCGTAATCATGGTCATAGCTGTTTCC
T3 Promoter
T3 primer binding site
T7 Promoter
T7 primer binding siteM13 –20 primer binding site KS primer binding site...
TTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGAATTGGGTACCGGGCCCCCCCTCGAGGTCGACGGT...
Kpn I
SK primer binding site...KS primer binding site
...ATCGATAAGCTTGATATCGAATTCCTGCAGCCCGGGGGATCCACTAGTTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCA...
Xho I
Sac IBstX IEcoR IEcoR V Sac IISpe ISma I Xba IPst IHind III
Bsp106 I
Cla I BamH I
Not I
Eag I
EcoO109 I
Dra II
Apa I
Acc I
Hinc II
Sal I

